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SUMMARY
Lipoprotein (a) (Lp(a)) has a complex structure which includes two 
apolipoproteins, apolipoprotein B (which is also present in other serum lipoproteins) and 
apolipoprotein (a) (which is unique to Lp(a)). Raised serum concentrations of Lp(a) have 
been associated with an increased risk of coronary heart disease.
Commercially-available Lp(a) assay systems suffer from poor analytical 
performance. In this study, cell lines secreting anti-Lp(a) antibodies are identified using a 
series of immunoassay-based screening tests. Monoclonal antibodies developed from these 
cells lines are used (in conjunction with commercially-available polyclonal anti-Lp(a) 
antibodies) to develop a two-site time-resolved fluoroimmunoassay for Lp(a) in human 
serum. This assay format requires one antibody to be immobilised onto the surface of a 
microtitre plate and a second antibody to be labelled with an element from the lanthanide 
series (europium) which, under certain reaction conditions, is fluorescent. Protocols for 
the labelling of polyclonal and monoclonal antibodies with europium are presented in this 
thesis.
Various combinations of anti-Lp(a) antibodies are used in assay development. The 
combination found to give the best assay performance with the minimum of interference 
from other biomolecules was:- a monoclonal anti-apo (a) capture antibody with a europium- 
labelled polyclonal anti-apo B detection antibody. Data obtained during the optimisation of 
antibody concentrations, sample dilution and reaction times is also presented. In the 
optimised assay, 200jjl of a 1:1000 dilution of serum is incubated with the capture antibody 
for three hours. Following a wash step, immune complexes are detected fluorimetrically 
after incubation with a europium-labelled second antibody for two hours.
The performance of the assay is compared to that of commercially-available kit 
assays. The time-resolved fluorescence assay is shown to be more precise and to have a 
much wider working range (1-1500 mg/L) than the commercial assays. However, data 
from analysis of samples distributed as part of an external quality control scheme is used to 
demonstrate the wide inter-assay variability ofLp(a) measurements.
Measured Lp(a) concentrations in a series of human serum samples demonstrate the 
highly skewed distribution previously reported in adult Caucasian populations. No 
significant differences are observed in the mean serum Lp(a) concentrations of males and 
females and no correlation could be made between age and serum Lp(a) concentration in the 
adult population studied. In a limited study, a wide day-to-day percentage variation in 
serum Lp(a) concentration is demonstrated in one subject.
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CHAPTER 1 
INTRODUCTION
Lipids are. present in human plasma in four distinct forms
(i) Fatty acids - are straight-chained compounds of varying length which may be 
saturated (containing no carbon-carbon double bonds) or unsaturated (containing one 
or more C-C double bonds). Free, or non-esterified fatty acids (FFA or NEFA) which 
are carried in the blood bound mainly to albumin, are an immediately-available source 
of energy. Fatty acids may also be esterified with glycerol to form glycerides.
(ii) Triglycerides - consist of glycerol esterified with three fatty acids.
(Hi) Phospholipids - are complex structures containing triglycerides together with 
hydrophilic phosphate groups and other hydrophobic moieties such as nitrogenous 
bases.
(iv) Cholesterol - has a sterol ring structure which is the precursor of various steroids 
molecules. Approximately two-thirds of serum cholesterol is esterified as cholesterol 
esters.
Lipids are hydrophobic and are therefore transported in body fluids as soluble 
lipid/protein complexes called lipoproteins. Lipoproteins consist of a core of 
insoluble (non-polar) triglyceride and cholesterol esters enclosed by soluble (polar) 
proteins, phospholipids and free cholesterol. The protein components may be divided 
into five principal groups known as apoproteins A, B, C, D and E.
Lipoproteins vary in size and composition, and are commonly classified by 
density using ultracentrifugation. There are four main classes: high density lipoprotein 
(HDL) and low density lipoprotein (LDL) transport cholesterol, whereas very low 
density lipoprotein (VLDL) and chylomicrons transport triglycerides. A fifth class, 
IDL (intermediate density lipoprotein), usually occurs as a transient intermediate 
during the metabolism of VLDL to LDL 0).
Raised concentrations of plasma lipids may result in the accumulation of lipid 
in tissues, particularly in the endothelium of arterial walls, leading to cell damage fil. 
However, there is considerable evidence that, whereas increased concentrations of 
LDL are associated with cardiovascular disease, an elevated concentration of HDL
protects against cardiovascular disease. This is presumably due to its role of 
transporting cholesterol from peripheral tissues for excretion (ri.
Lipoprotein (a) (Lp(a)) is a plasma lipoprotein that has characteristics similar 
to LDL. Both contain apolipoprotein Bioo (apo B) but in Lp(a) (unlike LDL) the apo 
B is linked to apolipoprotein (a) (apo (a)) by disulphide bridges. Interest in lipoprotein 
(a) has grown enormously over the last decade as elevated plasma concentrations 
have been linked to an increased risk of coronary heart disease
1.1 The discovery of Lipoprotein (a).
Lp(a) was first described by Berg in 1963 who attempted to demonstrate 
antigenic differences in the human lipoproteins migrating in the beta region (3) of 
serum protein electrophoretic strips by immunising rabbits with a human LDL 
fraction. The immune sera produced when absorbed with LDL present in test serum 
samples, detected a serum antigen in some but not in all individuals. Positive 
reactors were designated, Lp(a+), and negative reactors, Lp(a-). Much of the early 
characterisation of the protein was performed by Berg in the mid-1960 s: 
ultracentrifugation showed that Lp(a) antigen was present in the lipoprotein density 
class 1019-1063 g/L Family studies indicated that the presence of the Lp(a) 
antigen was genetically determined, being found in 30-40% of subjects studied in a 
variety of populations
At this time, Lp(a) was considered to be a genetic variant of LDL (5). 
However, chemical studies performed in the early 1970 s disproved this hypothesis: 
Ehnholm, Simons and Garoff demonstrated that although Lp(a) had a lipid 
composition similar to LDL, it contains significantly more carbohydrate than LDL 
and has pre-beta electrophoretic mobility When serum was subjected to 
ultracentrifugation, the low density pre-beta lipoproteins "floated" but Lp(a) "sunk". 
Lp(a) was therefore referred to as "sinking pre-beta lipoprotein" Lp(a) has also 
been found in other ultracentrifugation fractions: Utermann and his co-workers
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detected Lp(a) in the 1060-1120 g/L density fraction while studies of the narrow 
density class, 1050-1060 g/L, showed the presence of HDL, LDL and Lp(a)
In the early 1980s the structure of the Lp(a) lipoprotein was published 
independently by three groups of workers Lp(a) is a complex macromolecular
structure containing a high molecular weight glycoprotein termed apolipoprotein (a) 
(apo(a)) linked to apo B by disulphide bonds. The structure of Lp(a) will be described 
in more detail later in this introduction.
Positive association between raised plasma concentrations of Lp(a) and 
increased risk of myocardial infarction was first described by Renninger et al in 
1965. Furthermore, increased concentrations of slow pre-beta lipoprotein were 
demonstrated in electrophoresis of serum from patients with atherosclerotic disease 
This protein was subsequently demonstrated to be Lp(a), Following these 
observations there has been much interest in Lp(a) as a independent marker of 
coronary heart disease and many papers have been published on the subject. 
However, quantitative assay of Lp(a) has yet to find a place in the test repertoire 
offered by most hospital laboratories in Great Britain. This may be due to 
deficiencies in the analytical technique, difficulties in interpretation of results, or 
perhaps more importantly, because no effective treatment for lowering serum Lp(a) 
concentrations is yet available.
1.2 Inheritance of Lipoprotein (a).
The inheritance of lipoprotein (a) was first investigated by Berg and his co­
workers in 1967. Analysis of serum from the members of 500 Austrian families 
demonstrated that Lp(a) inheritance was compatible with a simple dominant 
Mendelian trait under the control of two alleles termed Lp® and Lp® However, this 
interpretation was challenged by two groups in the early 1970 s who noticed that the 
distribution of Lp(a) in similar sized Caucasian populations was continuous but highly 
skewed 08,i9)^  with most subjects falling in the low concentration range. This was not 
compatible with Berg's theory. Extended family studies by Sing et al concluded
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that one major gene with a polygenic background determined plasma Lp(a) 
concentrations whereas Hasstedt et al  ^Hasstedt and Williams and Morton et 
al have suggested that Lp(a) concentrations are controlled by two or three alleles 
that determine overlapping distributions. The nature of this postulated locus remains 
undefined, and to this day the mode of Lp(a) inheritance is not completely 
understood. The apo (a) gene and protein has also been detected in old world 
primates and hedgehogs but not in other animals.
1.3 Physicochemical structure of Lp(a).
The structure of Lp(a) has been extensively investigated. Lp(a) consists of 
two apolipoproteins, apo (a) and apo B, linked by a disulphide bridge (or bridges). 
Apo (a) can be quantitatively removed from Lp(a) by ultracentrifugation under 
reducing conditions. The resulting apo(a)-deficient lipoprotein is found in the same 
fraction as LDL while the essentially lipid-free apo (a) is recovered as the lower 
fraction on ultracentrifugation Fless and his co-workers have shown that apo 
(a)-deficient Lp(a) is a larger particle than LDL, and contains comparatively more 
triglycerides. The density of intact Lp(a) is greater than LDL, while apo (a)-deficient 
Lp(a) is the same as LDL It may therefore be concluded that the major 
differences between the physicochemical properties of Lp(a) and those of LDL result 
from the presence of apo(a).
Little was known about the structure of Lp(a) until the mid 1980 s when 
studies by Fless and Scanu and Gaubatz et al established that apo (a) was a 
glycoprotein with a high degree of polymorphism between individuals resulting in 
molecular weights higher than, lower than or equal to the molecular weight of apo B 
(which is approximately 500 kDa). Hence Lp(a) varies in size between 400 and 838
kDa (30,31)
Kringles (derived from the old Norse kringla) are ring shaped structures with 
78 - 82 amino acids, stabilised by three internal disulphide bonds which are present in 
various plasma proteins involved in coagulation and fibrinolysis (33,34) Amino acid
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sequence data demonstrated that apo (a) is made predominantly out of kringle 
structures, containing one kringle 5 domain and between 5 and 37 kringle 4 domains. 
In addition apo (a) also contains a serine protease region which has 94% structural 
homology with plasminogen but has no enzymatic activity (35) Thus, the size 
differences observed in apo (a) phenotypes are due primarily to the number of kringle 
4 repeat units although some differences in glycosylation of the protein may also 
contribute (3^\ Plasminogen also contains the kringle 4 and 5 domains, but kringles 1, 
2 and 3 (which are found in plasminogen) are not present in Lp(a). The high degree of 
homology between plasminogen and apo (a) is exemplified by the cross-reactivity of 
antibodies raised against each protein (^ ’^ 36) by the fact that, like plasminogen, 
apo (a) is retained by lysine-sepharose chromatography columns (3^\
The wide variation in the molecular mass of apo (a) (and hence Lp(a)) results 
in considerable variation in the number of isoforms (6-23) observed in various human 
populations (3®* 39)^  Lp(a) isoforms are usually analysed using immunoblotting: 
Following electrophoresis in a polyacrylamide gel (under reducing conditions) the 
separated Lp(a) isoforms are blotted onto a nitrocellulose membrane. Lp(a) is labelled 
with a specific antibody and the resulting immune complexes are detected using a 
second (anti-species) antibody covalently coupled to an enzyme such as horseradish 
peroxidase or a radioisotope such as ^^ 3; (38) The separated Lp(a) isoforms may then 
be classified according to their relative electrophoretic mobility compared to that of 
apo B and assigned molecular masses by comparison with the migration of marker 
proteins of known molecular weights (38). Thus the F isoform (400 kDa) has a faster 
electrophoretic mobility than apo B, the B isoform (460 kDa) has the same mobility 
as apo B, and the SI, 82, S3 and S4 isoforms (520, 580, 640 and 700 kDa 
respectively) each have slower mobility than apo B. Whereas each of the 
aforementioned species migrate as a single band, other isoforms (BSi, BSz, BS3, S1S2, 
S2S3, S2S4, S3S4) migrate as doublets. The method described by Utermann et al (38) 
employs a primary polyclonal rabbit anti-Lp (a) antibody followed by a ^25i_iabelled 
anti-rabbit second antibody. In spite of the sensitivity of this technique (90 ng of
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Lp(a), equivalent to a plasma concentration of -70 mg/L), 121 out of 247 (49%) 
subjects studied had plasma Lp(a) concentrations below the detection limit. Of the 
remaining 126 subjects, 14 had a doublet isoform (the most common being S2S3 
which was detected in 4 subjects), no subject had the F isoform and only 4 subjects 
had the B isoform. However, the larger SI - S4 isoforms were found in 18,33, 33 and 
25 subjects respectively.
There appears to be a significant inverse relationship between the molecular 
mass of apo (a) isoforms and plasma Lp(a) concentrations (3Ü, Smaller isoforms 
(which are present at much lower frequency in the population) are associated with 
high plasma Lp(a) concentrations, while the larger isoforms (which are found at a 
much higher frequency) are associated with lower plasma Lp(a) concentrations. 
However, a 100-fold variation in plasma Lp(a) concentration has been observed 
amongst individuals with the same isoform (30,
1.4 Distribution of Lp(a) in human populations.
Many studies of Lp(a) distribution in human populations have been 
performed. Berg's early qualitative assays showed consistent proportions of positive 
reactors (those exhibiting the Lp(a+) antigen) within various ethnic groups. Thus, 
around 35% of various white populations, 34% of American blacks and 30% of 
Greenland eskimos were positive for Lp(a). However, a significantly lower incidence 
of positive reactors was observed in Labrador Indians (2%) and natives of Easter 
Island (8%) (^^\ One of the first quantitative population studies was performed in 
Sweden (^ )^ where a highly skewed distribution of serum Lp(a) concentrations is 
found. Two-and-a-half percent of the population had Lp(a) concentrations above 480 
mg/L, the value was chosen as their upper reference value for human serum Lp(a) 
concentrations. This distribution pattern was reproduced in studies involving adult 
Japanese males (^^ and other Caucasian populations (38,43-45)^  all of which showed 
the same skewed distribution with a median concentration of -120-150 mg/L. 
However, some interesting variations have been observed. A study by Viikari et al in
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Finland in 1990 (^ 3) quantitated Lp(a) in serum from 2465 Finnish children and young 
adults between the ages of 9 and 24, The usual skewed distribution pattern and 
median concentration were observed and there was no difference in serum Lp(a) 
concentration between boys and girls, or between age groups. However, when the 
population was divided according to region, it was apparent that an excess of low 
values occurred in subjects from West Finland. Interestingly, a higher incidence of 
coronary heart disease was seen in East Finland. Guyton et al described a population 
of black American men and women which showed a bell-shaped distribution of 
serum Lp(a) concentration with the mean value double that of the white American 
population. The population of the Indian subcontinent have an Lp(a) distribution 
intermediate between other Caucasians and blacks while the Lp(a) distribution in 
the Chinese population is more skewed than in other populations (3i) (with a greater 
proportion of low values). These findings may suggest that serum Lp(a) 
concentrations are race-dependent .
One study measured serum Lp(a) during the first year of life. 
Concentrations were shown increased from a mean value of 40 mg/L at birth up to 78 
mg/L at 3 months and 108 mg/L at 6 months of age. The mean adult concentration 
was quoted at 140 mg/L. In contrast to adults, no significant differences in Lp(a) 
concentrations have been demonstrated between black and white neonates (30),
1.5 Serum Lp(a) concentrations in health and disease.
A positive correlation between high serum Lp(a) concentrations and an 
increased incidence of atherosclerotic disease has been thoroughly documented (51-83) 
The concentration of Lp(a) considered to be abnormal was reassessed by Dahlen et al 
in 1986 (^ (^ ). He studied a group of 307 American males and females and found that a 
Lp(a) concentration of 300 mg/L corresponded with the 70th percentile of the serum 
Lp(a) distribution. This concentration was found to be a threshold, below which 
Lp(a) seemed to have no effect on coronary artery stenosis risk scores in males or 
females below the age of 56.
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The regulation of plasma Lp(a) concentrations is not fully understood. The 
major site of Lp(a) synthesis appears to be in the liver since liver transplant recipients 
adopt the apo (a) isoform of the donor Although Lp(a) and LDL both contain apo 
B. they are metabolically distinct lipoproteins and, unlike LDL, Lp(a) does not appear 
to be a by-product of VLDL metabolism Lp(a) can be associated with 
triglyceride-rich particles found in individuals with hypertriglyceridaemia but 
cholesterol feeding (which can substantially increase serum concentrations of apo B 
and LDL) has little effect on serum Lp(a) concentrations
The mechanism of Lp(a) degradation is uncertain. Studies in vivo suggest that 
the LDL receptor plays a role in the catabolism of Lp(a) (88-90)^  although other studies 
suggest that this is not a major clearance route (91,92) Subjects with an apo B 
mutation that abolishes binding to the LDL receptor do not have increased 
concentrations of Lp(a) (3^ ). However, subjects with a defect in the LDL receptor 
itself do have elevated serum Lp(a) concentrations (^ 3). a  study by Hofmann et al (^ )^ 
showed that Lp(a) binds to the LDL receptor with an affinity similar to that of LDL, 
and that clearance of human Lp(a) is markedly increased when it is administered to 
transgenic mice that overexpress human LDL receptors.
Structural similarities between Lp(a) and plasminogen are thought to be a 
possible cause of the increased risk of atherosclerosis in subjects with raised serum 
Lp(a) concentration. Tissue plasminogen activator acts on plasminogen to release 
plasmin, a proteolytic enzyme responsible for the breakdown of fibrin clots. Lp(a) 
might interfere with plasmin generation by (i) competing with plasminogen for cell 
surface receptors (^ 5-9?)^  (ii) by inhibiting the conversion of inactive plasminogen to 
active plasmin (98,99) gj. b y  competing with plasmin for binding sites on fibrin 
(99,100) bas been shown that the kringle 4 domain in Lp(a) avidly binds to fibrin in 
vitro (^ (^ (^ ). Fibrin is abundant in early atheromatous plaques (^ (^ )^ and there is strong 
evidence that serum Lp(a) binds to this fibrin (in preference to other apo B-containing 
serum proteins such as LDL) (^ (^ \^ The Lp(a) may then be modified by oxidation and 
taken up by macrophages, thus contributing to foam cell formation within plaques
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In vitro studies have shown that Lp(a) competes in equimoiar concentrations 
with plasminogen for binding to plasminogen receptors on vascular endothelial cells 
However, using immunochemistry, Lp(a) could not be detected on plasminogen 
receptors on colon or breast carcinoma cells Although Lp(a) was thought to 
have no enzymic activity it has been shown to bind to and cleave (albeit slowly) 
the extracellular matrix protein, fibronectin, in vivo
Several groups have described variations in serum Lp(a) concentrations in 
acquired medical conditions. For example, in acute renal disorders associated with 
proteinuria, serum Lp(a) concentrations are two-fold higher than during remission 
(105,106) Haemodialysis had no effect on serum Lp(a) concentrations in a group of 
patients with chronic renal failure who also had a raised a serum Lp(a) concentration 
(107,108) Elevated Lp(a) concentrations have also been observed in type 1 (insulin- 
dependent) diabetics with microvascular disease (^09-ii2) jjj ^ypg 2  (non insulin- 
dependent) diabetics with poor glycaemic control ( ^   ^3 ) However, improved 
glycaemic control was associated with a lowering of Lp(a) concentrations in the latter 
group (112-114) Qne study suggested that all diabetics show a tendency towards higher 
serum Lp(a) concentrations (^ 3^)
Originally Lp(a) was believed to be an acute phase protein (H^), serum 
concentrations of which increase during various acute inflammatory conditions. 
However, recent studies suggest that this is not the case. For example, Slunga et al 
(11^  ^showed that Lp(a) concentrations rose only very slightly following myocardial 
infarction and that this rise did not correlate with rises in the concentrations of other 
acute phase proteins such as orosomucoid, C-reactive protein and alpha-1-antitrypsin. 
However, the rise in Lp(a) concentration did correlate with elevations of other plasma 
lipids. These findings were supported by similar observations in a group of patients 
with rheumatoid arthritis
The concept of an hepatic site of Lp(a) synthesis is further supported by two 
groups. One group showed that serum Lp(a) concentrations were very low in patients 
with alcoholic cirrhosis while the other study involved 18 patients with biliary
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cirrhosis or chronic active hepatitis 14 of these subjects were found to have 
undetectable serum concentrations of Lp(a). However, the other four had raised 
serum Lp(a) concentrations, suggesting an additional extra-hepatic site for Lp(a) 
synthesis. An interesting study by Kervinen et al showed a rapid increase in 
plasma Lp(a) concentration in some alcoholic men four days after ethanol withdrawal. 
The most dramatic increase in concentration was approximately two and a half times 
the basal level, although some subjects showed little or no increase. The 
immunosuppressive drug, cyclosporin, was associated with an elevation in serum 
Lp(a) concentration in a group of renal transplant recipients when compared to a 
control group receiving alternative immunosuppressive therapy Possible
nephrotoxic effects of cyclosporin were not considered to be responsible for the 
increase in Lp(a) since renal function was similar in each group of patients.
Diet appears to have little effect on plasma Lp(a) concentration (2,29,30) Lipid 
lowering drugs such as hydroxymethylglutaryl coenzyme A reductase inhibitors 
(simvastatin, pravastatin), bile acid séquestrants (cholestyramine), fibric acid 
derivatives (clofibrate, gemfibrozil) and the antioxidant, probucol, which have a 
significant lowering effect on plasma LDL concentrations have no effect on plasma 
Lp(a) concentration (31.123-128) However, Lp(a) concentrations can be decreased by 
treatment with nicotinic acid (which can be used to treat peripheral vascular disease) 
or a combination of nicotinic acid and the aminoglycoside antibiotic drug, neomycin 
(which inhibits the transport of non-esterified fatty acids to the liver). However, the 
hepatotoxicity of these drugs precludes their use in long-term treatment (127,128) |q_ 
acetyl cysteine (which is thought to reduce the formation of disulphide bonds within 
Lp(a)), has been reported to successfully lower serum Lp(a) concentration in two 
patients (^^^\ although other workers were unable to reproduce these results (^ O^) The 
anabolic steroid, stanozolol, (^3i) ^nd androgenic progestogens (a component of 
hormone replacement therapy) also reduce plasma Lp(a) concentrations (^ 32) This 
action of progestogens may, to some extent counterbalance the undesirable increases 
in the plasma concentration of other lipids observed with these drugs (^ 33) Hormonal
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regulation of serum Lp(a) concentration has also been observed during the treatment 
of prostatic carcinoma: whereas Lp(a) concentrations rose slightly in patients treated 
by orchidectomy, Lp(a) concentrations decreased in those undergoing oestrogen 
treatment (^ 34) one group has described a rise in serum Lp(a) concentrations up to 
the 25th week of normal pregnancy, with a rapid return to normal post-partum which 
may be related to the hormonal changes of pregnancy (^ 35) pish oils, which decrease 
the secretion of VLDL, also appear to lower plasma Lp(a) concentrations (123,137,138) 
but the effectiveness of fish oils as an Lp(a)-lowering treatment has yet to be 
confirmed. Cigarette smoking, which is a recognised risk factor for coronary artery 
disease, has no significant effect on serum Lp(a) concentration (139-140) since there is 
no suitable safe means of lowering plasma Lp(a) concentration it may be that the 
treatment of individuals with a high risk of coronary artery disease should be based on 
reducing other risk factors (^^).
1.6 Qualitative and quantitative measurement of Lp(a).
Early qualitative methods for the detection of Lp(a) employed gel diffusion 
under non-denaturing conditions in agarose or starch gels (7»^ ). Immune complexes 
were visualised using lipophilic stains such as Sudan black or Oil red. However, the 
subsequent availability of specific antibodies to Lp(a) has allowed the development of 
quantitative assays. The first generation of quantitative assays (radial 
immunodiffusion (RID) (^ ^^ ) and electroimmunodiffusion (EID) (^ ^^ )) employed 
precipitation of antigen-antibody complexes within gels (19,143-145) However, RID 
suffers from several problems: the technique is insufficiently sensitive to measure 
Lp(a) in all human serum samples and, more importantly, size differences between 
the Lp(a) particles influences their mobility in the gel (^ ^^ ) Most studies performed in 
the 1970 s, which correlated raised concentrations of Lp(a) with an increased risk of 
cardiovascular disease, used EID assays. The technique had adequate sensitivity and 
reproducibility but was very labour-intensive and not suitable for automation.
Radioimmunoassay (RIA) (^^7)fgr Lp(a) was developed in the late 1970 s (®^ .^
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The method is sensitive and specific but uses radioisotopic reagents with limited 
shelf-life. Immunoradiometric assays (IRMA) (148,149) developed later (^ 30) 
These two-site ("sandwich") assays employ a primary antibody adsorbed onto a solid 
phase, and a second antibody labelled with The analytical performance of these 
assays is adequate and large batches of samples may easily be assayed using 
automated equipment.
Immunoturbidimetric and immunonephelometric assays have also been used 
to quantitate Lp(a) (I5i,i52) gg^ gh of these techniques is based on the precipitation 
reaction between Lp(a) and an anti-Lp(a) antibody in solution. In the turbidimetric 
assay, the formation of antigen-antibody complexes prevents monochromatic light 
passing through a cuvette, the amount of light blocked being proportional to the Lp(a) 
concentration. In nephelometric assays, light scattered by the antigen-antibody 
complex is measured at right angles to the incident light. Although each of these 
methods are easy to automate, they suffer from several drawbacks. For example, they 
are very susceptible to interference from other biomolecules (eg high concentrations 
of triglycerides (^ 33)^  in addition, repeated freezing and thawing of serum samples 
appears to decrease measured Lp(a) concentrations to a greater extent than is 
observed using alternative analytical methods (^ 34) Although nephelometric methods 
are highly sensitive and do not require sample dilution they are strongly influenced by 
variation in the size of the Lp(a) isoforms which have associated variations in their 
light scattering properties (*33) However, they are simple and quick to perform, and 
large numbers of samples may be analysed using automated equipment. However, 
analytical results appear to be less reproducible than those obtained using IRMA 
assays (*32).
The wide availability of microtitre plate assays in the early 1980 s led to the 
development of a number of enzyme-linked immunosorbent assays (ELISA) for Lp(a) 
(155-166) These assays use an anti-Lp(a) antibody adsorbed onto plastic microtitre 
plates to capture Lp(a) in the sample (which has previously been diluted between 500- 
and 2000- fold). A second anti-Lp(a) antibody, conjugated to an enzyme such as
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horseradish peroxidase, is used to detect the amount of Lp(a) bound to the capture 
antibody. The immobilised enzyme subsequently catalyses the production of a 
coloured product from an added substrate. The intensity of the colour produced 
(which is measured photometrically) is proportional to the Lp(a) concentration in the 
sample. ELISA assays are easy to perform, easy to automate and (with good assay 
technique) highly reproducible. However, they suffer from a limited working range 
(-10-800 mg/L) which means a minority of subjects have apparently unmeasurable 
serum concentrations of Lp(a). In 1992 ten out of fourteen participants in a national 
quality assurance scheme run from Manchester, UK (*34) one of three 
commercially available ELISA kits. The major advantages of using these kits were 
that no in-house reagent production was required, the reagents had a long shelf life 
and there were no major safety hazards. However, the cost of commercial ELISA kits 
is quite high, typically around £200 for a kit sufficient to analyse 36 serum samples in 
duplicate.
An interesting alternative approach to the measurement of Lp(a) was made by 
Lou et al in 1992 (*^ 7)^  who developed a semi-quantitative immunochromatographic 
method. This assay uses a nitrocellulose membrane strip coated in each of four 
regions by an anti-Lp(a) monoclonal antibody. Purified, dried Lp(a), coated with 
colloidal selenium (rusty red in colour), is immobilised on a glass fibre pad at one end 
of the strip. The dried Lp(a) is rehydrated by the addition of 25p,l of plasma (or SOjiil 
of whole blood : an anti-erythrocyte antiserum is also impregnated in the glass fibre 
pad to immobilise red cells). The mixture of sample Lp(a) and selenium-coated Lp(a) 
diffuses through the nitrocellulose membrane strip and competes for binding in the 
regions coated with anti-Lp(a) antibody. If the Lp(a) concentration in the serum 
sample is low, the binding capacity of the first antibody region is sufficient to bind all 
the serum- and selenium-coated Lp(a). Hence, only the first antibody coated region 
would be coloured. In samples with very high Lp(a) concentrations the binding 
capacity of all four antibody-coated regions would be saturated with Lp(a), and each
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region would therefore be coloured red. Analytical time is only -10 minutes for each 
sample, and the results are highly reproducible and agree well with ELISA assays.
1.7 Time-resolved fluorescence immunoassay (DELFIA®) for Lp(a).
D_issociation Enhanced Lanthanide FluorohnmunoAssay (DELFIA®) (also 
known as time-resolved fluorescence immunoassay) has been used since the early 
1980 s as an alternative to radioisotopic and enzyme-labelled immunoassays. Most of 
the development of DELFIA® was performed in Scandinavia by Hemmila and his co­
workers (168-173) A large number of DELFIA® kits are now commercially available for 
the measurement of peptide hormones such as thyroid-stimulating hormone, lutenising 
hormone (LH), follicle-stimulating hormone (FSH) and human chorionic gonadotrophin 
(hCG), the steroid, cortisol, proteins such as prostate specific antigen and 
alphafoetoprotein and drugs such as digoxin (174-179) More kits for other analytes are 
becoming available each year.
The sensitivity of conventional fluorescence immunoassays is severely limited 
by unavoidably high background fluorescence due to the scattering of light by solvents, 
solutes and particles in solution and from the inherent fluorescence of biomolecules 
including proteins and NADH. The fluorescent decay times of these compounds is in 
the region of 10 nsec. Time-resolved fluorescence overcomes the problem of 
background fluorescence by using a fluorophore with a decay time in excess of 500 
microseconds (psec). Hence, a fluorescent signal measured at a time greater than 10 
nsec (and less than 1 millisecond) will be free from interference by background 
fluorescence. The elimination of background fluorescence together with a fluorimeter 
capable of measuring fluorescent counts in excess of 1 million/sec has allowed the 
development of highly sensitive assays with a working range spanning up to 5 orders of 
magnitude. Time-resolved fluorescence immunoassays employ reagents which are 
stable for up to one year and have none of the safety hazards associated with 
radioimmunoassays (*80).
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Most commercial DELFIA® assays are in the form of a two-site immunoassay 
with a primary monoclonal "capture" antibody which is coated onto a microtitre plate 
and a secondary monoclonal antibody labelled with a fluorophore such as europium. 
Europium (Eu), with an atomic weight of 152, is a member of the lanthanide group of 
elements which also includes samarium , terbium and dysprosium. It is similar in 
atomic size to iodine (atomic weight 125) which is commonly used as a label in 
radioimmunoassays, although, in contrast to iodine, europium cannot be directly 
covalently coupled to a protein. However, europium forms a stable complex with the 
chelating agent, N 1 -(p-isothiocyanateobenzyl)diethylenetriamine-N*N^N^N^-tetra 
acetic acid (DTTA). This complex contains an isothiocyanate group which reacts with 
free amino groups in proteins to form a stable covalent thiourea bond. Using 
Eu/DTTA chelates individual antibody molecules may be labelled with up to 10-20 
atoms of europium.
The Eu/DTTA chelate supplied in the kit marketed by Wallac at a cost of 
around £150 is sufficient to label enough antibody for at least one hundred 96-well 
microtitre plate assays. Highly purified bovine serum albumin may be added to a final 
concentration of 0.1% (w/v) to aid stability and the labelled antibody is stored at +4 ®C. 
When stored correctly, the labelled protein is stable for at least one year.
The labelled antibody itself is non-fluorescent. However, after it has bound to 
the 'captured* antigen (immobilised onto the microtitre plate), europium is dissociated 
from the secondary antibody by the addition of enhancement solution (a buffer 
containing a beta diketone, 2-naphthoyl-trifluoroacetate at pH 2-3; a detergent, Triton 
X-100; and a fatty acid derivative, trioctylphosphine oxide). In solution, the europium 
ions form highly fluorescent chelates stabilised inside micelles. Lanthanide chelates 
have a long fluorescence decay time, a very large Stokes shift (i.e. the difference 
between the excitation wavelength (340 nm) and the emission wavelength (613 nm)), a 
sharp emission peak and a high fluorescence intensity In addition, the chelates are 
very stable and, if evaporation is avoided, solutions may be left in microtitre plates for 
up to 24 hours before fluorescence measurements are made. Dual-labelled diagnostic
23
kits are now available in which two analytes may be measured simultaneously using the 
same microtitre plate (eg LH & FSH). One detection antibody is labelled with 
europium and the other is labelled with samarium. Since europium and samarium have 
significantly different emission wavelengths (Eu = 613 nm, Sm = 643 nm) and different 
fluorescent lifetimes (Eu 730 psec and Sm 50 psec), the fluorimeter can easily 
distinguish between the two. This produces assays with high sensitivity and specificity 
for each analyte. In theory, it should be possible to measure four different analytes in a 
single microtitre plate using four lanthanide labels, although this has yet to be 
achieved.
The availability of the Wallac labelling kit brought DELFIA® assays into the 
research environment. The labelling of antibodies and other proteins is very simple: 1 
mg of the antibody to be labelled is added to 0.2 mg of europium-DTTA chelate and 
incubated overnight. Labelled antibody is separated from free label using gel filtration 
chromatography. Labelling yield (the number of europium atoms on each antibody) 
may then be estimated by calculating the europium and protein concentrations of the 
labelled antibody solution. The former may be estimated by comparison with a 
europium solution of known molarity and protein concentration may be estimated using 
the method described by Lowry (iBi) or by measuring absorbance at 280 nm 
Typical yield is around 10 europium atoms/antibody. Labelling yield can be increased 
by varying the incubation time, buffer pH and reaction temperatures: a longer 
incubation time, higher buffer pH and higher temperature each increase europium 
incorporation. However, extremes of these parameters may result in protein 
dénaturation, especially when monoclonal antibodies are employed. A yield >3, but 
<20 europium atoms/antibody results in optimal assay performance.
Time-resolved fluorescence immunoassays have been developed for use in 
many fields of biomedical science. For example, applications have been found in 
microbiology, biochemistry and immunology, and a method has also been described for 
quantifying DNA (183-196) indeed, it may be that use of time-resolved fluorescence
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immunoassays will become as widespread in the 1990 s as radioimmunoassays were in 
the 1970 s.
1.8 Interassay variability for Lp(a).
The wide range of methods employed in the measurement of Lp(a) has given as 
much as 2-3 fold variation in the results obtained from patient samples. This was 
demonstrated by analysing results obtained from samples sent out by the external 
quality control scheme based in Manchester, UK. to laboratories around the 
country for Lp(a) measurement. Laboratories participating in the scheme used one of 
five different methods, three were ELISA kits, one an IRMA kit and the other an 
immunoturbidimetric assay. The differences in Lp(a) results obtained for any particular 
sample could be attributed to one of two major variations in assay design, namely the 
antibodies used and the standardisation material employed.
The first Lp(a) assays to be developed employed polyclonal antibodies. To 
eliminate cross-reactivity with apo B, antisera were pre-absorbed with LDL 
However, the high degree of homology between apo (a) and plasminogen also caused 
cross-reactivity problems (197-201) Qjjg approach to resolving these problems was the 
development of a two-site assay (e.g. an ELISA) using an anti-apo (a) antibody as the 
"capture” antibody and an anti-apo B antibody to detect immune complexes 
(156,158,160,162) Alternatively two anti-apo (a) monoclonal antibodies directed against 
different epitopes may be employed (155,160,161)
A document with specific recommendations for the generation and selection of 
monoclonal antibodies for the measurement of apolipoproteins AI and B was published 
in 1990 by the International Federation of Clinical Chemistry (IFCC) It has been 
suggested that these recommendations may also be applied to anti-Lp(a) monoclonal 
antibodies (53). Since it is important that antibodies should react consistently with all 
Lp(a) isoforms, selected antibodies should be directed against an epitope located on the
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kringle 5 or protease domains, one copy of each being present in each isoform. 
However, an antibody directed against an epitope on the kringle 4 domain would give a 
variable analytical performance depending on the number of domains present in a 
particular isoform . For this reason, the use of an anti-kringle 4 antibody as a 
detection antibody should be avoided However, it may be acceptable to use an 
anti-kringle 4 antibody to capture Lp(a), providing it reacts with all isoforms 
identically. The IFCC document states that manufacturers should clearly indicate the 
immunochemical characteristics of the monoclonal antibodies marketed for use in 
apolipoprotein immunoassays. Unfortunately, however, this has yet to be achieved.
The calibration of Lp(a) assays was, and still is, a major problem Assays 
with an anti-apo (a) capture antibody and an anti-apo B detection antibody ((a)/B assay) 
permit the expression of results on a molar basis since each molecule of Lp(a) contains 
only one apo B subunit. However, the calibration of assays using two anti-apo (a) 
antibodies ((a)/(a) assay) is usually in mass units. Commercial assays, using either 
combinations of antibodies (i.e. (a)/B or (a)/(a)) are generally calibrated in mg/L (or 
mg/dl).
Accuracy of Lp(a) immunoassays is highly dependant on the availability of a 
primary Lp(a) standard of known concentration, which may be employed to assign 
values to a reference material which, in turn, may be used to assign values to 
calibrators used in the assay itself Delipidated Lp(a) undergoes extreme self­
association and irreversible aggregation and is therefore unsuitable as a primary 
standard (53). Purified Lp(a) has been used as a calibrant, but no consensus has been 
reached regarding its preparation. Lp(a) may be purified from the 1050-1120 g/L 
density fraction of plasma using ultracentrifugation followed by gel filtration 
chromatography (^ '^ )^. However, the yield from this method is low (15-20%). Albers 
et al purified Lp(a) from the 1060-1090 g/L HDL density fraction of plasma (7,19,87). 
however, this preparation was not considered to be representative of total plasma 
Lp(a). Lp(a) has also been purified from plasma by using anti-apo(a) affinity 
chromatography columns (i^ )^.
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An alternative approach to the standardisation of Lp(a) assays is to produce a 
primary standard of purified apo (a). Apo (a) may be purified relatively easily from 
Lp(a) by the reduction of disulphide bonds followed by centrifugation to remove 
lipids and apo B Alternatively, apo (a) has been synthesised using recombinant
DNA technology However, apo (a) calibrants suffer from several drawbacks; the
most important being that they cannot be used in assays utilising anti-apo B detection 
antibodies. In addition, monoclonal antibodies may react unpredictably in some 
assays systems: for example, those raised against purified (reduced) apo (a) 
appear to react poorly with intact (non-reduced) Lp(a) particles while those raised 
against intact (non-reduced) Lp(a) react poorly with (reduced) apo (a) This 
suggests that some apo (a) epitopes are destroyed under reducing conditions If 
this is the case, recombinant apo (a) (containing intact disulphide bonds) is more 
likely to share the epitopes found on native Lp(a) than of reduced apo (a)
Accurate determinations of the protein mass of primary standard material 
cannot overcome the problem of intra-individual variations in Lp(a) particle 
composition, size and hydrated density. In particular, assays using two anti-apo (a) 
antibodies make no correction for differences in the mass of the various Lp(a) 
isoforms. Since the choice of Lp(a) calibrant remains arbitrary, a consensus is 
required before direct comparison of results from different assays may be made 
At present most commercial Lp(a) calibrants consist of lyophilised human plasma 
from subjects with elevated serum Lp(a) concentration. Calibrants may contain a 
single isoform of intermediate size or a mixture of several of the isoforms The 
latter approach may minimise differences resulting from variations in isoform size.
The (a)/B assay format has some advantages: Lp(a) may be quantitated on a 
molar basis, the quantitation should be independent of isoform size (providing the 
capture antibody recognises all isoforms equally) and there should be no interference 
from plasminogen. A recent comparison of Lp(a) measurements in serum 
samples containing each of the main groups of isoforms demonstrated that 
significantly lower Lp(a) concentrations were obtained with the lower molecular
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weight isoforms, F, B and SI, when analysed using an (a)/B assay compared to the 
(a)/(a) assay. This difference was reversed with the higher molecular weight 
phenotypes, S2, S3 and S4. The (a)/(a) assay employed in this study was the Macra 
ELISA kit (Terumo Medical Corp., Elkton, MD 21921, USA) which is currently 
commercially available only in the USA. The kit contains a monoclonal antibody 
(ID l) raised against the kringle 4 domain as the solid phase capture antibody, and a 
peroxidase-conjugated anti-Lp(a) polyclonal antibody as the detection antibody 
The discrepancies described above may be due to the anti-kringle 4 antibody 
'capturing' the different isoforms of apo (a) with different affinities or the polyclonal 
detection antibody binding to the variable number of kringle 4 domains present in the 
apo (a) of each isoform.
Many recent publications of quantitative Lp(a) measurements have used 
ELISA kit assays similar to the one described above. However, it may be impossible 
to compare results obtained from two groups of workers who use different kits and 
different standardisation procedures.
1.9 In vitro stability of Lp(a).
In addition to antibody and standardisation problems, the stability of Lp(a) in 
vitro has been questioned (205) Por any laboratory test to be of clinical use the 
potential causes of result variability must be understood. Panteghini & Pagani (^ ®^) 
suggested that there was a considerable time-dependant biological variation in serum 
Lp(a) concentration within individuals: Blood samples were collected weekly for five 
weeks from a group of 4 healthy males and 4 healthy females. Lp(a) quantitation 
using the Macra ELISA kit gave a mean Lp(a) concentration of 140 mg/L with a 
mean within-subject variation of 8.5%. This represents a larger biological variation 
than occurs, for example, with serum total cholesterol. However, the assay used in 
this study had poor analytical performance; at -100 mg/L the within-run precision 
calculated from 20 replicates gave a coefficient of variation of 10.5%, while the 
between-batch imprecision calculated from 2 0  replicates gave a coefficient of
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variation of 15.7%! This relatively poor performance must have compounded any 
biological variation.
T h ese  au th o rs  a lso  ex am in ed  th e  e ffec ts  o f  sam p le  s to rag e  an d  sh o w ed  th a t 
se ru m  sam p les  w e re  s tab le  fo r  u p  to  15 day s a t +4®C an d  fo r u p  to  th ree  m o n th s  a t 
-20°C. O th e r w o rk e rs  (82,208,209) j^ p o rt s im ila r fin d in g s a lth o u g h  o n e  g ro u p  su g g ested  
th a t h ig h e r  m o le c u la r  w e ig h t L p (a ) iso fo rm s u n d erg o  co n s id e rab le  c ry o p rec ip ita tio n  
d u rin g  s to ra g e  re su ltin g  in  lo ss  o f  im m u n o reac tiv ity  (13.156,210) a  s tu d y  in v o lv in g  
sam p les  s to red  fo r 6  m o n th s a t e ith e r -20 o r -70 ®C an d  th en  an a ly sed  u s in g  R ID  a n d  
e a c h  o f  tw o  E L IS A  a ssa y s  (^®*) d e m o n s tra te d  n o  d iffe re n c e s  in  m e a su re d  L p (a )  
c o n c e n tra tio n  u s in g  th e  E L IS A  assa y s , b u t a  46% re d u c tio n  in  m e a su re d  L p (a )  
c o n c e n tr a t io n  w a s  a p p a re n t  u s in g  R ID . T h is  f in d in g  w a s  c o n s is te n t  w ith  
c o n c en tra tio n s  m easu red  in  215 se ru m  sam p les  s to red  a t  -40 ®C fo r  an  av e rag e  o f  ten  
y ea rs  w h ich  w e re  62% lo w er b y  R ID  (^ ® )^ th an  b y  E L IS A , H en ce , R ID  ap p ears  to  b e  
m o re  sen sitiv e  to  sam p le  d e te rio ra tio n  d u rin g  sto rag e  th an  E L IS A .
Recently, it has been reported that lyophilisation of serum consistently results 
in lower measured Lp(a) concentrations when compared to original fresh serum 
irrespective of the analytical method employed However, the addition of
crystalline sucrose to a final concentration of 0.6 M appears to significantly improve 
the stability of Lp(a) in lyophilised serum(^ ^®*^ ^^ ), although the addition of liquid 
sucrose (to the same final concentration) was less effective. It was thought that the 
loss of Lp(a) immunoreactivity following lyophilisation may result from some form 
of self-aggregation of either (or both) apo B and apo (a) (^ ^
Median levels of Lp(a) measured in samples from 17 healthy blood donor 
volunteers indicated no difference between serum samples and plasma anticoagulated 
with K%EDTA No data has been published concerning the effects of other 
commonly used anticoagulants such as lithium heparin and potassium oxalate/sodium 
fluoride.
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1.10 Use of Lp(a) measurements.
At present, the use of serum Lp(a) measurements is limited. The analysis 
cannot be used as a screening test for coronary artery disease because assay protocols 
and calibration have not been standardised. Therefore, it may be that the assay 
should only be offered to patients attending specialist lipid clinics who have 
substantially raised plasma cholesterol concentrations, or evidence of premature 
coronary heart disease with no other identifiable risk factors. In the latter group, the 
finding of raised serum Lp(a) concentration might significantly increase risk status. It 
is also possible that certain apo(a) isoforms are more "atherogenic" than others 
Awareness of the significance of serum Lp(a) measurements is being increased 
through articles in international scientific journals such as Scientific American 
which may stimulate the demand for quantitation of Lp(a). Eventually, if assay 
problems are overcome, the measurement of Lp(a) and its isoforms together with 
HDL and cholesterol, may become commonplace in the routine clinical chemistry 
laboratory.
1.11 Aims of the project.
1 To select, produce and classify at least two anti-Lp(a) monoclonal antibodies.
2 To purify these antibodies and label them with europium.
3 To develop and optimise a time-resolved fluoroimmunoassay for Lp(a).
4 To assess the performance of the assay and compare it to the performance of
other commercially available assays for Lp(a).
5 To assess possible interference in the assay by other biomolecules.
6  To use the assay to measure serum Lp(a) concentrations in various 
groups of patients.
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CHAPTER 2
MATERIALS AND METHODS
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2.1 REAGENTS AND MATERIALS.
Microtitre plates.
Nunc-Immuno Module Maxisorp F I6  Unframed Microtitre strips.
80 strips/box. 2 x 8  wells/strip. Catalogue number. 469914.
Nunc, Roskilde, DENMARK, (fax 45 42 350105)
Wells are certified to have absorbance readings within +/- 0.005 absorbance units 
from the mean value.
SOLUTIONS
Reagents were purchased from the following companies.
BAYER pic (Technicon’l 
Evans House,
Hamilton Close,
Basingstoke,
Hampshire,
U.K.
RG21 2YE.
MERCK Ltd (BDHL
Marketing supplies (BDH lab supplies),
Merck House,
Poole,
Dorset, UK.
BH15 IBR.
SIGMA
The Sigma Chemical Co Ltd.
Fancy Road,
Poole,
Dorset, UK.
BH7 7NH.
ICN BIOMEDICALS Ltd.
Lincoln Road,
Cressex Industrial Estates,
High Wycombe,
Bucks, U.K.
HP12 3XJ.
Bicarbonate buffer. 0.1 M. pH 9.2
NaHCO] 8.40 g/L of deionised water.
Na2C0 3  (anhydrous) 10.60 g/L of deionised water.
Add 100 ml of NaaCOs solution to 900 ml NaHCOg solution. Adjust to pH 9.2 if 
necessary.
Store at room temperature.
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Phosphate-buffered saline (PBS) pH 7.4
Solution is made up as a concentrate and diluted 25-fold for use,
Na2HP04 .12 H2O 73.4 g
Na H2PO4 (anhydrous) 5.4 g
NaCl 219 g
Make up to 1.0 litre with deionised water and adjust pH to 7.4 if necessary.
Dilute this stock solution 1 in 25 in deionised water for use.
Store at room temperature.
Citrate buffer. 0.1 M. pH 4.0.
Trisodium citrate 29.41 g/L of deionised water.
Citric acid (anhydrous) 21,0 of deionised water.
Add 410 ml of trisodium citrate solution to 590 ml of citric acid solution. Adjust pH 
to 4.0 if necessary.
PLATE ’BLOCKING' REAGENTS
Bovine Serum Albumin 
Sigma - code A-7030 
Fatty acid-free.
Human Serum Albumin 
Sigma - code A-1887
Essentially fatty acid-free (approx 0.005%) Prepared from fraction V albumin.
Bovine Gamma Globulin 
ICN code - 820412
ANTIBODY SCREENING ASSAY REAGENTS
Supernatant diluent.
PBS + 1% (w/v) bovine serum albumin (BSA).
Store frozen in 40 ml aliquots at -20°C.
Wash Buffer.
PBS + 0.5% (v/v) Tween 20 detergent.
Store at room temperature.
Peroxidase-Abntibody conjugate diluent.
PBS + 1% (w/v) BSA + 0.1% (v/v) Tween 20.
Make up fresh daily.
ABTS solution.
ABTS = 2,2' - Azino bis (3 - ethylbenzthiazolinesulfonic acid) Sigma code A-1888 
Dissolve 1.0 g of ABTS in 1.0 L of 0.1 M Citrate buffer pH 4,0.
Divide into 50 ml portions. Stored at -20°C the reagent is stable for at least 1 year.
Hydrogen peroxide solution.
Sigma code H-1009 
30% solution. Store at 4®C.
Working Assay Substrate.
Dilute the hydrogen peroxide 1:100 in deionised water.
Just before use add lOjil diluted H2 0 .2/ml ABTS.
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OTHER CHEMICALS
Bilirubin
Sigma - code B 4126
Crystalline preparation from bovine gall stones. Store dessicated below 4°C.
Plasminogen 
Sigma - code P-5661
DETERGENTS
Benzethonium chloride 
Sigma - code B 8879
Brii 99 (20 Oleyl ether)
Technicon - Supplied as a 20% (v/v) solution.
Cholic acid (sodium salt)
Sigma - code C 1254
CHAPS (3-[(3-cholamidopropyl)-dimethylammonio]-l propane sulfonate. 
Sigma - code C 3023
Deoxvcholic acid (sodium salt)
Sigma - code D 6750
Tween 20 (Polyoxyethylenesorbitan monolaurate)
BDH - code P 1379
Triton X-100 (Polyoxyethylene ethers)
BDH - code 30632
Triton X-115. X-405 
Sigma
Wetting Agent W 
Technicon - code T21-1298
CHROMATOGRAPHY REAGENTS
Sephadex G-25 
Sigma code G-25-150
Sepharose 6B 
Sigma code 6B-100
Hvdroxvapatite (calcium phosphate hydroxide - type I) 
Sigma code H-0252
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TIME-RESOLVED FLUOROIMMUNOASSAY (DELFIA®) REAGENTS
DELFIA Labelling buffer : 50 mmol/l NaHCOs. 0.9% (w/v) NaCl pH S5.
NaHCOg 4.20 g
NaCl 9.0 g
Make up to 1.0 litres with deionised water. Adjust pH to 8.5 if necessary.
DELFIA Elution Buffer : 50 mmolA Tris HCl. 0.9% (w/v) NaCl. pH 7.8.
Trizma Base 6.065 g
NaCl 9.0 g
Sodium Azide (NaNg) 0.5 g
Dissolve in 800 ml of deionised water, adjust pH to 7.8 with concentrated 
hydrochloric acid. Make up to 1.0 L with deionised water.
DELFIA Column decontamination buffer : 10 mmol/l potassium hydrogen phthalate. 
0.001 %DTPA.pH4.0.
Potassium hydrogen phthalate 2.04 g
DiethyleneTriamine-Pentaacetic Acid (DTPA) 0.01 g
Make up to 1.0 litres with deionised water, adjust pH to 4.0 if necessary.
These reagents are stable for at least 6  months at room temperature if bacterial 
contamination is avoided.
DELFIA Assay Buffer. Wash Buffer & Enhancement solution.
These solutions are supplied by Wallac in their commercial assay kits; additional 
reagents may be purchased individually from Wallac if required.
Certain component concentrations are not stated by the manufacturer.
DELFIA Assay Buffer 
Tris-HCl Buffer, pH 7.8 1.0 litres
Bovine serum albumin 5.0 g
Bovine globulin 0.5 g
Tween 40 0.2 ml
DTPA
Inert red dye. Store at 4®C.
DELFIA Wash buffer 
Tris-HCl buffer, pH 7.8 
Tween 20
German II (preservative)
Supplied as a 25-fold concentrate. Dilute with deionised water for use.
Store at 4®C.
DELFIA Enhancement solution 
A buffer of pH 2-3 containing:- 
2 -naphthoyl-trifIuoroacetate 
Trioctylphosphine oxide 
Triton X-100
Store at room temperature away from direct sunlight.
WALLAC rU.Kl Ltd.
Davy Avenue,
Knowlhill,
Milton Keynes 
MK5 8PH.
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COMMERCIAL ANTIBODIES & STANDARD
THE BINDING SITE LIMITED.
Institute of Research and Development,
Birmingham Research Park,
Vincent Drive,
Birmingham, UK.
B15 2SQ.
Anti-Human Apolipoprotein B.
The Binding site - Economy grade; code PE086 (lot A6718)
Cyto grade (IgG fraction) ; code PC086 (lot A4419)
Antibody developed in sheep, economy grade contains whole antiserum; cyto grade 
has undergone solid phase adsorption and has a total protein content of 10-20  mg/ml.
Anti-Human Apolipoprotein B peroxidase conjugate.
The Binding Site - code PP086 (batch G2669)
Cyto grade antiserum conjugated with horseradish peroxidase in Tris/saline buffer, 
pH 7.4, immunoglobulin : enzyme molar ratio of 1:1.
TMMUNO LTD.
Arctic House,
Rye Lane,
Duncton Green,
Sevenoaks,
Kent, UK.
TN14 5HB
Anti-Human Lp(a) antiserum.
Immuno - code 4845005 
Antibody developed in sheep.
Human Lpfa) reference standard.
Immuno - code 4395005
Lyophilised, defibrinated pooled human plasma with stabilisers added to prevent 
irreversible destruction of apo B-containing proteins during the freeze drying process. 
Concentration assigned by comparison with a primary standard of purified Lp(a).
The standard was reconstituted with 0.5 ml of deionised water using a Gilson pipette 
checked for accuracy and precision. After mixing on a roller-mixer for 30 minutes the 
standard was divided into 30pJ portions and stored frozen at -20°C.
The frozen standards were stable for at least three months.
DAKQ Ltd.
16 Manor Courtyard,
Hughenden Avenue,
High Wycombe,
Bucks, U.K.
HP13 5RE
Donkey Anti-sheep IgG peroxidase conjugate.
Dako - code P I63 (lot number 39)
Sheep Anti-mouse IgG (whole molecule) peroxidase conjugate (affinity purified). 
Sigma immunochemicals - code A-5906 (lot number 040H8800)
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2.2 COMMERCIAL Lp(a) ASSAY KITS.
The following kits were commercially available in the United Kingdom at the 
time of this study. Each kit contained sufficient reagents to assay approximately 35 
patient samples in duplicate. The cost of each kit was -£200.
ELISA ASSAYS.
Immuno Immunozym®kU, 
IMMUNO LTD.
Arctic House,
Rye Lane,
Duncton Green,
Sevenoaks,
Kent, UK.
TN14 5HB
This kit (214) uses a one-step two-site assay protocol. Microtitre plates coated 
with a polyclonal anti-apolipoprotein (a) antibody are used to capture Lp(a) which is 
then detected by a horseradish peroxidase-conjugated monoclonal anti-apolipoprotein 
(a) antibody. Although Immuno state that the antibodies recognise the kringle 4 
domain of Lp(a) they claim that this does not affect quantitative measurements (2i5).
The assay uses a 1:500 dilution of sample which is added to the antibody- 
coated microtitre plate together with the peroxidase-conjugated antibody. After a 1 
hour incubation at 20°C, the microtitre plate is washed four times and a substrate, 
tetramethylbenzidine (TMB), is added. The substrate is incubated for 30 minutes at 
room temperature. TMB is then cleaved by horseradish peroxidase to produce a blue 
coloured product which turns yellow on addition of sulphuric acid which also stops 
the reaction. The absorbance of the solution at 450 nm is then measured and used to 
generate a standard curve from which the unknowns may be calculated.
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Innogenetics Innotest Lp(a) kit,
INNOGENETICS.
Kronenburgstraat 45,
B2000
Antwerp,
Belgium.
This kit (216) uses a monoclonal anti-apolipoprotein (a) capture antibody and a 
horseradish peroxidase-conjugated anti-apolipoprotein B detection antibody. The 
assay is performed in two steps. In the first step, samples diluted 1:2000 in assay 
buffer are incubated with the capture antibody for two hours at 37®C. The microtitre 
plate is then washed and detection antibody is added for 1 hour at 37®C. The assay is 
then completed using a procedure identical to that of the Immunozym® assay.
Biopool TintElize Lp(a) kit 
PORTQN CAMBRIDGE Ltd.
Lanwades Business Park,
Kennett,
Newmarket, Suffolk, U.K.
CB8 7PW
This kit (212) uses anti-apolipoprotein (a) antibodies (type not specified) as 
both capture and detection antibodies. Samples are diluted 1:2601 and incubated with 
capture antibody for 2 hours at room temperature. Without washing the plate, 50^ 11 
of horseradish peroxidase-conjugated antibody is added to each well and incubated 
for a further 1 hour at 25°C. The plate is then washed and a coloured product is 
generated as in the other Lp(a) ELISA assays. This assay kit is unusual in that the 
Lp(a) standards are supplied in lyophilised form incorporated into the well of the 
microtitre plate.
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IMMUNORADIOMETRIC ASSAY 
Pharmacia apo(a) IRMA,
This is a two-site immunoradiometeric assay (218) using two anti- 
apolipoprotein (a) monoclonal antibodies directed against different antigenic 
determinants of apolipoprotein (a). One of these antibodies is labelled with 125% and 
the other is bound to a solid phase (sepharose particles). Before analysis, samples are 
mixed at a 1:1 ratio with a pretreatment solution (thought to contain a reducing agent) 
which releases apolipoprotein (a) from the Lp(a) particle. After the incubation step, 
the sample is further diluted 1:21 in a buffer. The diluted sample is then incubated 
simultaneously with both antibodies for 1 hour at 20®C. Immune complexes are 
precipitated with polyethylene glycol and centrifuged to produce a pellet. The liquid 
supernatant is then decanted and the gamma radiation in the pellet is measured.
Unlike the ELISA assays, the IRMA assay is calibrated in terms of 
apolipoprotein (a) units/L and the manufacturers state that, although no direct 
conversion can be made to mass units due to variations in the size of apolipoprotein 
(a) isoforms, an approximate conversion factor of 1 unit of apo (a) = 0.7 mg Lp(a) 
may be applied.
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2.3 ABSORBANCE MEASUREMENTS in MICROTITRE PLATES.
Absorbance readings were made using the V-max microtitre plate reader 
(Novo Biolabs) linked to an Acorn Archimedes computer running Novoclone® 
microtitre plate reading software. Monochromatic light was produced by means of 
filters, the selection of which is controlled by the computer software. To make an 
absorbance reading, the microtitre plate is simply inserted into the instrument and 
readings commenced under software control. The absorbances of the 96 wells of a 
microtitre plate may be measured in less than 30 seconds. End-point readings were 
taken for all assays in this project. The absorbance data obtained may be printed out 
in its raw form or used to generate a standard curve and calculate unknowns.
2.4 MEASUREMENT OF TIME-RESOLVED FLUORESCENCE ( 219).
Conventional fluorescence assays have severe limitations in sensitivity due to 
high background fluorescence from biomolecules (especially proteins) and light 
scattering effects. The time-resolved fluorescence technique uses a label whose 
fluorescence is measured after a delay time during which background fluorescence 
has decayed completely. This label is europium, a member of the lanthanide series of 
elements, which has a very long fluorescence decay time and a large Stokes' shift (i.e. 
the difference between the excitation wavelength of 340 nm, and the emission 
wavelength of 608 nm). In addition, the emission peak is of a very narrow band of 
wavelengths.
Most fluorescent compounds (fluorophores) have decay times of less than 10 
nsec. In contrast, europium has a decay time of 730 p.sec. Therefore, if fluorescence 
readings are taken at a time interval of between 400-800 |xsec, no background 
fluorescence will be measured. In the time-resolved fluorimeter, europium is pulsed 
with light at the excitation wavelength for 1000 cycles/second. In the period between 
these pulses, fluorescence is measured and the counts from each reading are 
accumulated. A diagrammatic representation of this procedure is presented in figure 
2.1.
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A typical time-resolved fluorescence assay may generate in excess of 1 
million fluorescence counts for standards at the highest analyte concentration and less 
than 1000 counts for the zero standard. This enables highly sensitive assays to be 
produced with a working range up to 5 orders of magnitude.
Fluorescence readings are made using the DELFIA® 1234 research 
fluorimeter. The practical aspects of the procedure are very simple. Following 
release of europium from the secondary antibody by addition of enhancement 
solution, the microtitre plate is loaded into the measurement chamber of the 
instrument, exposed to monochromatic light at the fluorescence excitation wavelength 
of 340 nm (1000 pulses/sec), and the emitted fluorescence is detected. The 
fluorescence counts data may be sent to a data handling software package such as 
Pharmacia's Multicalc or taken directly from the fluorimeter. The instrument is pre-set 
to read fluorescence emission from each well for 1 second. This time cannot be 
adjusted and, after reading one well, movement onto the next well is made 
automatically. 1 2 x 8 microtitre plates are read in a specific way, rows of 12 wells are 
always read in a left-to-right direction which cannot be adjusted. Consequently assays 
should be set up with standards along the top 12 wells of the microtitre plate so that 
they are read first. The time taken to read a complete 96 well plate is around 3 
minutes. If required, the microtitre plate may be read several times since 
fluorescence (according to the manufacturers) is stable for up to 24 hours if 
evaporation of solutions is avoided.
2.5 ASSAYS ON THE DuPONT DIMENSION®AR ANALYSER
The following analytes were measured on the DuPont Dimension® AR 
autoanalyser, all reagents were supplied in the flex® reagent pack used on the 
instrument. The instrument performance was checked by analysis of quality control 
materials.
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Total Bilirubin.
The method is a modification of the Jendrassik and Grof procedure 
Bilirubin in solution is solubilised by dilution in a solution of caffeine/sodium 
benzoate/acetate and disodium EDTA. Diazotised sulfanilic acid (formed by 
combining sodium nitrite and sulfanilic acid at low pH) is added to the bilirubin 
which is then converted to diazo-bilirubin, a red chromophore, which absorbs light at 
a wavelength of 540nm. Bichromatic blanking’ is performed by a taking a second 
absorbance measurement at 700nm. The absorbance increase is proportional to 
bilirubin concentration in the sample, all forms of bilirubin including the conjugated, 
unconjugated and delta forms are measured.
Total Protein.
The method is based on Henry’s modification (221) of the biuret reaction first 
introduced by Kingsley (222).
Cupric ion (Cu++) reacts with peptide bonds of proteins at an alkaline pH and 
a blue copper (II) protein complex is formed, the colour intensity of which is 
proportional to the total protein concentration of the sample. Absorbance of solutions 
are read at 540nm and at a bichromatic blanking wavelength of 700nm. Absorbance 
is proportional to protein concentration in the sample under test. Sodium potassium 
tartrate is added to the reagent to prevent the formation of insoluble copper (II) 
hydroxide.
Albumin
Albumin was measured by a dye-binding technique described by Carter and 
Louderback et al (223). The method is more specific for human albumin than other dye 
binding procedures. In acetate buffer pH 4.9 containing a surfactant solubilising 
agent, albumin binds to the dye Bromocresol Purple (BCP); the albumin-BCP 
complex absorbs light at 600nm. The absorbance is proportional to the albumin 
concentration of the sample under test.
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CHAPTER 3 
GENERATION and PURIFICATION 
OF ANTI-Lp(a) MONOCLONAL ANTIBODIES
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The monoclonal antibodies used in this project were generated by Drs. T. 
Wooley and T. Wang (Dept. Clinical Biochemistry, Cambridge.) by immunisation of 
mice with a highly purified preparation of Lp(a) (Immuno). A panel of antibody- 
secreting cell lines thus generated were characterised using a series of immunoassays 
designed by the author in conjunction with Dr. Wang. The production and collection 
of mouse ascitic fluid was performed by Dr. Wooley.
Two independent antibody screening assays were initially employed to 
determine (a) whether the cell culture supernatants contained any antibodies, and (b) 
whether these antibodies were directed against Lp(a). In subsequent screening assays 
the antibodies were used in competition with other antibodies of known specificity in 
an attempt to determine whether they were directed against epitopes on the apo B or 
apo (a) regions ofLp(a).
3.1. SCREENING FOR THE PRESENCE OF ANTIBODIES IN CELL 
CULTURE SUPERNATANTS.
3.1.1 Method 1 (figure 3.1)
Microtitre plates were coated with a 1:3400 dilution of an 800 mg/L Lp(a) 
standard preparation (Immuno) which contains both Lp(a) and other human plasma 
proteins in 0.1 M bicarbonate buffer, pH 9.2. 150|xl of this solution was used to coat 
each well during an overnight incubation at 4°C. During this incubation both Lp(a) 
and other proteins bound non-specifically to the plastic of the well (a process known 
as 'passive diffusion' (224)). After coating, the plate was washed four times with a wash 
solution of phosphate-buffered saline (PBS) containing 0.5% (v/v) Tween 20 
detergent to remove unbound standard.
Cell culture supernatants were diluted 1:10, 1:100 and 1:1000 in supernatant 
diluent (which consisted of PBS supplemented with bovine serum albumin (BSA) at a 
concentration of 10 g/L). lOOp.1 aliquots of diluted supernatant were pipetted, in 
duplicate, into the Lp(a)-coated microtitre plate wells. Sheep anti-human Lp(a) 
antiserum (Immuno) was used as a positive control, while fresh cell culture medium
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(containing no antibodies) was used as a negative control. The microtitre plate was 
covered and incubated overnight at 4°C.
The microtitre plate was then washed four times and 125p,l of a 1:250 dilution 
(in supernatant diluent/0.1% (v/v) Tween 20) of an ovine anti-mouse IgG-horseradish 
peroxidase (HRP) conjugate (Sigma Immunochemicals) was pipetted into wells. As a 
positive control, 125p,l of donkey anti-sheep IgG-HRP conjugate (1:1000) was added 
to replicate wells. The microtitre plate was incubated at room temperature for 1 hour, 
washed four times, and 150jil of the HRP substrate, ABTS (see Materials and 
Methods) was pipetted into each well. The microtitre plate was incubated at room 
temperature in the dark until the absorbance of the most intensely coloured well 
(measured at 490 nm using a V-max microtitre plate reader) was greater than 1.0, but 
less than 2.0. A 'blank' absorbance reading (taken at 405 nm) was subtracted from the 
reading at 490 nm.
This screening method was designed to determine whether the cell culture 
supernatants contained any anti-human antibodies (of any specificity). Since the 
microtitre plate was coated with other human plasma proteins (in addition to Lp(a)), 
any mouse antibodies present in the cell culture supernatants that subsequently bound 
to the wells could be directed against either human Lp(a) or any of the other human 
plasma proteins present.
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Results.
In excess of 100 cell culture supernatants were screened using the procedure 
outlined above. Those supernatants giving the greatest absorbances are shown below. 
An absorbance greater than 0.2 indicates the presence of a mouse anti-human 
antibody.
Cell culture supernatant. Absorbance (490-405 nm)
1/7/A9 1.142
2/9/ClO 1.053
3/2/B5 1.021
1/7/E4 0.995
3/5/G5 0.965
4/1/H12 0.944
2/10/F4 0.924
1/8/F5 0.918
3/2/All 0.770
1/7/G12 0.722
Negative control 0.100
Cell culture supernatants with an absorbance below 0.2 were eliminated from the next
series of screening tests.
3.1.2 Method 2 (figure 3.2)
A two-site 'sandwich* assay using commercially-available antibodies directed 
against Lp(a) (either sheep anti-human apo B from The Binding Site' or sheep anti­
human apo (a) from Immuno) was used to screen for the presence of anti-Lp(a) 
antibodies. 150^1 of either the anti-apo B antibody (diluted 1:100) or the anti-apo (a) 
antibody (diluted 1:1000) were used to coat the microtitre plate by passive diffusion 
overnight at 4®C. Dilutions were made in bicarbonate buffer, pH 9.2. After 
incubation, the plate was washed four times and 75p,l of a 1:3400 dilution of Lp(a) 
standard (850 mg/L) in supernatant diluent was added to each well. The microtitre 
plate was covered and incubated at 4°C overnight.
The following day the plate was washed four times and cell culture 
supernatants (diluted 1:10, 1:100  and 1 :1000  in supernatant diluent), positive and
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FIGURE 3.1 :
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FIGURE 3.2 ;
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negative controls were added to the wells. Subsequently the assay employed the same 
protocol as method 1.
High absorbance indicate the presence in cell culture supernatants of 
antibodies directed against of Lp(a), although the method is unable to differentiate 
anti-apo (a) and anti-apo B specificities.
Results.
A series of -100 cell culture supernatants (which were positive in method 1) 
were screened. The absorbances obtained for each supernatant using either anti-apo 
(a) or anti-apo B coated microtitre plates are presented below.
Anti-apo (a) antibody.
Cell culture supernatant Absorbance (490-405 nm)
3/5/F5 1.196
2/9/ClO 1.135
1/H5 1.118
1/H12 1.058
4/1/H12 1.058
1/8/F5 0.936
2/10/F4 0.635
1/7/G12 0.233
1/7Æ4 0.201
3/2/F5 0.134
1/7/A9 0.116
3/2/All 0.091
Negative control 0.090
Anti-apo B antibody.
Cell culture supernatant Absorbance (490-405 nm^
3/5/F5 0.365
2/9/ClO 0.349
1/H12 0.332
1/H5 0.302
1/8/F5 0.292
2/10/F4 0.287
4/1/H12 0.274
1/7/A9 0.124
1/7/G12 0.091
Negative control 0.090
Absorbances for the other supernatants were less than 0.1.
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The use of these two screening tests (methods 1 & 2) allowed the rapid 
elimination of a large proportion of the panel of several hundreds of cell culture 
supernatants that might provide antibodies for Lp(a) immunoassays. It may be noted 
that some of the supernatants that were strongly positive in method 1 (1/7/A9 and 
3/2/B5) were only weakly positive in method 2, suggesting these were not anti-Lp(a) 
antibodies. However, two supernatants, 3/5/F5 and 2/9/C 10 (35f5/29clO) consistently 
produced high absorbance readings in each method. Aliquots of each of these cells 
were therefore injected into the peritoneal cavities of mice in order to generate 
monoclonal antibody-containing ascitic fluid. These ascitic fluids (containing either 
29c 10 or 35f5 anti-Lp(a) antibodies) were used in the next series of screening tests.
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3.2 DETERM INATION OF THE SPECIFICITIES OF ANTI-Lp(a) 
ANTIBODIES.
A series of assays were developed with an aim of identifying the epitopes of 
Lp(a) recognised by the monoclonal antibodies. The assays employed competition 
between the monoclonal antibodies and commercial antibodies of known specificities 
for binding sites on Lp(a).
3.2.1 Method 3 (figure 3.3)
This two-site assay employs competition between a commercial polyclonal 
antibody (bound to the microtitre plate) and the test monoclonal antibody (in solution) 
for binding to added Lp(a) (also in solution). If the test antibody bound an epitope of 
Lp(a) recognised by the immobilised antibody then less Lp(a) would bind to the 
microtitre plate. The bound Lp(a) is subsequently detected using an HRP-conjugated 
antibody directed against a different Lp(a) epitope to that recognised by the 
immobilised antibody. Hence, competition between the test antibody and the 
immobilised antibody for the same Lp(a) epitope results in decreased absorbance. In 
principle, however, it may be possible for both the test and immobilised antibodies to 
bind to the same region of Lp(a) with no competition. This is because the 
immobilised polyclonal antibody has, by definition, more than one binding site on 
Lp(a).
Commercial polyclonal anti-apo (a) or anti-apo B antibodies were used to coat 
microtitre plates (as in screening method 2). After coating with antibody, 75jil of 
Lp(a) standard (250 ng/ml) and 50pl of ascitic fluid (diluted 1:100 - 1:10000 as in 
method 2) were pipetted into the wells and incubated overnight at 4®C. The assay 
was then completed as in screening method 2 .
Results.
The absorbances obtained at each ascitic fluid dilution for each antibody were 
the same (data not shown). This finding suggests that binding of the monoclonal 
antibody to Lp(a) did not inhibit its binding to either of the commercial polyclonal
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capture or detection antibodies. Variations in the reaction conditions of these assays 
also failed to demonstrate any competition between the immobilised antibodies and 
the test antibodies.
3.2.2 Method 4 (figure 3.4)
This assay employs microtitre plates coated with an anti-apo (a) polyclonal 
antibody to capture Lp(a) present in 75pl of Lp(a) standard (25 ng/ml) during an 
overnight incubation at 4®C. After washing, 50|xl of mouse ascitic fluid (diluted 
1:10000) was added to each well together with 50pl of the commercial polyclonal 
anti-apo (a) or anti-apo B antibodies (diluted 1:10, 1:100 or 1:1000). These 
antibodies were added to compete with the monoclonal antibody for binding sites on 
the immobilised Lp(a). In some wells the commercial antibody was replaced by 50|il 
of diluent only (blank), in order to provide an estimate of the maximum binding of 
the monoclonal antibody to the immobilised Lp(a). Following incubation of the 
reaction mixture at room temperature for 4 hours, the assay was completed using the 
standard protocol (section 3.1). The absorbance reading in each well was 
proportional to the amount of monoclonal antibody bound to the immobilised Lp(a).
The assay relies on competition between the polyclonal and monoclonal 
antibodies for binding sites on Lp(a). Hence, displacement of the polyclonal antibody 
(of known specificity) suggests that the test monoclonal antibody is directed against 
the same epitope.
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FIGURE 3.4 :
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Results.
(i) 35fS monoclonal antibody (ascitic fluid).
Absorbances in the presence of a polyclonal anti-apo (a) antibody.
Polyclonal antibody dilution Absorbance (490-405 nm)
1:10 0.084
1:100 0.132
1:1000 0.184
Blank (maximum binding of 35f5) 0.183
Absorbances in the presence of a polyclonal anti-apo B antibody. 
1:10 0.172
1:100 0.185
1:1000 0.190
Blank (maximum binding of 35f5) 0.192
(ii) 29cl0 monoclonal antibody (ascitic fluid).
Absorbances in the presence of a polyclonal anti-apo (a) antibody.
Polyclonal antibody dilution Absorbance (490-405 nm)
1:10 0.099
1:100 0.138
1:1000 0.180 
Blank (maximum binding of 29c 10) 0.187
Absorbances in the presence of a polyclonal anti-apo B antibody. 
1:10 0.177
1:100 0.185
1:1000 0.180 
Blank (maximum binding of 29c 10) 0.196
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The decreases in absorbance obtained when an excess (-50 pg) of anti-apo (a) 
polyclonal antibody was added to the reaction mixture suggests that both of the 
monoclonal antibodies are directed against epitopes on the apo (a) region of Lp(a). In 
principle, the addition of relatively large amounts of polyclonal antibody may affect 
the binding of the monoclonal antibody to Lp(a) in a non-competitive manner. 
However, this possibility seems unlikely since the anti-apo B polyclonal antibody 
(also at ~50p,g) caused little or no displacement of the monoclonal antibody.
3.3 FURTHER CHARACTERISATION OF THE BINDING SPECIFICITIES 
OF35f5and29clO.
3.3.1 Introduction.
Possibly the simplest method of determining whether the monoclonal 
antibodies recognise epitopes on the anti-apo (a) or B regions of Lp(a) is to reanalyse 
serum samples found to have a high concentration of apo B and a low concentration 
of Lp(a) in assays using commercial anti-Lp(a) antibodies of known specificity. If, on 
reassay (after replacing one of these commercial antibodies with a monoclonal 
antibody), the samples give a completely different result, it is likely that the 
monoclonal antibody is directed against a different region of Lp(a) to that recognised 
by the polyclonal antibody it has replaced.
3.3.2 Method.
Analyses were performed using the time-resolved fluorescence assay (see 
chapters 5-7). Assays were developed using the following antibody combinations. 
Capture antibody Detection antibody
'Immuno' anti-apo (a) Binding Site' anti-apo B
'Binding Site' anti-apo B 'Binding Site' anti-apo B
35f5 'Binding Site’ anti-apo B
29cl0 'Binding Site' anti-apo B
55
The apo B standard (1005 mg/L) from the Pharmacia apo B IRMA kit was 
used in the assay. Analysis in the (a)/B time-resolved fluorescence Lp(a) assay 
showed it to contain a low concentration (-150 mg/L) of Lp(a). The standard was 
diluted 1:500 in assay buffer and subjected to doubling Dilutions to produce a series 
of standards. These standards, together with 7 serum samples, were analysed using 
each of the antibody combinations.
The fluorescence counts for each apo B standard were used to construct a 
standard curve for each of the antibody combinations. The apo B concentrations of 
the unknowns were estimated from these curves.
Results are presented in table 3.1
Table 3.1 : Apo B concentrations (mg/L) for seven serum samples measured in time- 
resolved fluorescence assays using an anti-apo B detection antibody with each of four 
different capture antibodies.
Sample anti-apo (a) anti-apo B 35f5 29cl0
1 850 235 884 >1005
2 >1005 278 >1005 >1005
3 >1005 351 >1005 >1005
4 >1005 382 >1005 >1005
5 960 220 >1005 >1005
6 >1005 278 >1005 >1005
7 >1005 1036 >1005 >1005
It is apparent from these results that there is considerable disparity between 
the values obtained using the dual anti-apo B assay format (B/B) and those obtained 
using anti-apo (a)/anti-apo B antibody combination ((a)/B). Results using the 
monoclonal antibodies were similar those generated using the (a)-B assay format.
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These discrepancies may be explained as follows: the B-B assay measures apo 
B in both standards and unknowns and apo B present in Lp(a). In the (a)-B assay , the 
presence 1005 mg/L of apo B in the standard will not produce a fluorescence signal as 
apo B cannot bind to the capture antibody. However, the 150 mg/L of Lp(a) present 
in the undiluted standard will bind to the capture antibody, as will any Lp(a) present 
in the serum samples. If these serum samples had Lp(a) concentrations in excess of 
150 mg/L , the fluorescence signals would be greater than that of the standard, hence 
the 'apparent* apo B concentration would be greater than the actual apo B 
concentration in the standard (1005 mg/L). It may be seen that this occurred for 6 out 
of 7 of the serum samples. The assays using 29c 10 or 35f5 capture antibodies showed 
a similar result pattern to the (a)-B assay. This was taken to be further evidence that 
the antibody was directed against an epitope on the apo (a) region of Lp(a). Further 
studies on the characterisation of the monoclonal antibodies will be presented in 
chapter 5.
3.4. ANTmODY PURIFICATION.
3.4.1 Introduction.
Approximately 5 ml of mouse ascitic fluid containing either the 29c 10 or 35f5 
monoclonal antibody were collected. Since these fluids are likely to contain other 
proteins (particularly albumin) which would also be labelled during the europium 
labelling procedure (chapter 4), initial purification of the antibody was necessary.
3.4.2 Methods.
Ammonium sulphate precipitation.
3.15 ml of saturated ammonium sulphate solution was added to 4.5 ml of 
ascitic fluid (containing either 29c 10 or 35f5) and the mixture was stirred 
continuously for 30 minutes at room temperature. Following centrifugation at 10,000 
g for 20 minutes at 20®C, the supernatant was discarded and the precipitated protein
f
pellet was resuspended in 1.0 ml of 80 mmol/L phosphate buffer. The suspension was
57
then dialysed overnight at 4®C against 80 mmol/1 phosphate buffer to remove the 
ammonium sulphate.
Hydroxyapatite chromatography.
The dialysate containing 29c 10 antibody was further purified by adsorption
chromatography using a hydroxyapatite column eluted with a phosphate buffer
gradient (10-250 nmiol/L). Eighty-four fractions of 2 ml were collected using an
automated fraction collector (Pharmacia), and the absorbance of the eluate was
continuously monitored at 280 nm. A plot of absorbance at 280 nm versus fraction
number is shown in figure 3.5. The eluants were used to coat microtitre plates for
Lp(a) assay (see chapter 4). These assays confirmed that fractions in the first peak
eluted from the column were free of anti-Lp(a) antibodies while the larger second
peak contained the 29c 10 antibody. Thirty fractions (2 ml each) corresponding to the
antibody peak were pooled and the absorbance of this solution was measured at 280
nm. The approximate protein concentration of the pool was estimated using the
equation 082);
IgG (mg/ml) = Abs 280 nm
1.34
The pooled antibody solution was concentrated using an Amicon 
concentration system employing a membrane which is permeable to molecules of less 
than 30 kD, but is impermeable to larger molecules. Using this technique, the 60 ml 
of pooled antibody solution was concentrated to a final volume of ~2 ml and the 
protein content was estimated by absorbance measurement at 280 nm. Surplus 
antibody not required for the europium labelling procedure was stored in 0.5 ml 
aliquots at -20°C after addition of sodium azide to 0.1% (w/v) as preservative.
3.4.2 Results.
Addition of ammonium sulphate to ascitic fluid should precipitate large 
proteins (e.g. antibodies) but not smaller proteins (e.g. albumin) which should remain 
in solution. However, the two absorbance peaks of the eluants from the
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hydroxyapatite column (figure 3.5) suggests that some smaller proteins had also been 
precipitated. The 60 ml of pooled 29c 10 antibody contained 13 mg of protein at 0.22 
mg/ml. The protein concentration was increased by filter concentration to 7.2 mg/ml. 
Since the total volume of the concentrated antibody solution was 1.7 ml, it is apparent 
that 94% of the protein present in the original fractions was recovered.
3.5 CONCLUSIONS.
A series of mouse hybridoma culture supernatants were screened using 
enzyme-immunoassays to identify cell lines producing anti-Lp(a) antibodies. 
However, these screening assays were unable to determine the epitope of Lp(a) 
recognised by the antibodies. The latter was achieved by comparison of fluorescence 
counts obtained for a serum sample (with a high apo B concentration and a low 
concentration of Lp(a)) measured using the time-resolved fluorescence assay with a 
series of antibodies of known specificities. Two antibodies (29c 10 and 35f5) both 
directed against apo (a) were purified for use in Lp(a) immunoassays.
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CHAPTER 4
PRACTICAL ASPECTS OF LANTHANIDE LABELLING
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4.1 Introduction.
All immunoassays employ a label that may be detected, quantitatively or 
qualitatively, by physical or chemical means. In a competitive immunoassay the 
(tracer) antigen is labelled, whereas in a two-site (or "sandwich") immunoassay an 
antibody is labelled. Conventional labelling materials include radioisotopes such as 
or 1251 (emitting beta and gamma radiation respectively) which may be detected by 
means of scintillation counters. Several radiolabelling procedures have been 
developed (225), These techniques are easy to perform but require expertise to 
consistently produce labels with the desirable specific activity. Many commonly-used 
radiolabelled antigens and antibodies are commercially available, although for 
research purposes, it is inevitable that some proteins (particularly those with little 
commercial demand) will need to be labelled in-house. Strict regulations control the 
use and disposal of radioisotopes in the United Kingdom. These state that iodinations 
(the incorporation of 2^5j into proteins), during which high intensity radiation is used, 
should be performed only in a designated room with lead shielding to protect the 
operator. Equipment is required to monitor the radioactive emissions and strict 
adherence to analytical protocols should be enforced to ensure that spillages and 
contamination of work areas is minimised. Any waste materials from the process also 
require special disposal procedures. Persons performing iodinations should undergo 
regular thyroid scans to ensure that 2^5; has not been absorbed and concentrated in the 
gland. 1251 is the most commonly-used radioisotopic label. Proteins labelled with this 
isotope have a limited shelf-life (-1-2 months) due to radiation damage of the protein 
itself and loss of radioactive emission intensity due to the short half life (6 weeks) of
1251,
Radioisotope stability and safety problems have encouraged the use of 
alternative non-isotopic materials as labels in immunoassays such as enzymes, 
fluorophores (molecules which absorb light at one wavelength and re-emit light at a 
higher wavelength) and chemiluminescent compounds (molecules which emit light 
during an oxidative chemical reaction). Enzymes are widely employed: for example.
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alkaline phosphatase and horseradish peroxidase are frequently used in commercial 
ELISA kit assays. It is possible to label proteins with enzymes 'in-house' but the 
procedures are more complex than iodinations. In the authors experience of in-house 
enzyme labelling, there has been a tendency for the enzyme to dissociate from its 
protein during prolonged (2-3 months) storage at 4°C which increases non-specific 
binding and assay imprecision. The enzyme acts on an added substrate to generate a 
coloured product which can be determined photometrically. This additional step in the 
assay generates additional analytical variability. The effect of assay temperature is 
particularly important: microtitre plates require careful equilibration of the whole 
plate to avoid temperature differences between inner and outer wells. These 'edge- 
effects' may significantly affect enzyme activity and lead to large analytical errors. 
The use of assays reliant upon absorbance measurements tends to limit their working 
range because, even if a high quality spectrophotometer is used, precise and accurate 
readings outside the range of 0.05-2.0 absorbance units are difficult to obtain. 
Therefore, even with high affinity antibodies and optimised assay protocols, the 
detection system will limit assay performance.
Fluorophores have been employed in many immunoassay systems but 
interference or quenching effects from other biomolecules have limited their use. 
However, the development time-resolved fluorimetry in the 1980 s overcame these 
problems (chapter 1) and this technique, together with chemiluminescence, appears to 
offer the greatest potential for the development of safe, sensitive and reproducible 
immunoassays. Both techniques require expensive, specialised instruments for the 
detection of fluorescence or chemiluminescence which may prohibit their use as a 
research tool. However, as more commercial assays have become available their use 
in routine clinical chemistry departments has become widespread: many will now 
own at least one of the instruments. The availability of a time-resolved fluorimeter in 
this department provided an opportunity to develop "in-house" time-resolved 
fluoroimmunoassays.
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4.2 Lanthanide labelling.
The theoretical aspects of lanthanide labelling and time-resolved fluorescence 
measurements have already been described in some detail in the introduction and 
Material and Methods sections. In this section, various practical aspects of lanthanide 
labelling are discussed, and antibodies labelled using this technique are characterised.
The initial aim of this project was to produce a set of labelled antibodies to be 
used (together with non-labelled antibodies) in two-site time-resolved immunoassays 
for Lp(a). The first antibody to be labelled with europium (Eu^+) was a 
commercially-available polyclonal anti-apo B antibody obtained from the 'Binding 
Site', Birmingham, UK. This antibody was chosen because of its availability in 
affinity-chromatography purified form at a high protein concentration.
Kits for lanthanide labelling were purchased from Wallac. The europium 
labelling kit contained a glass vial containing 0.2 mg of Europium-DTTA chelate 
(labelling vial), bottles of enhancement solution, Tris-HCl assay buffer and 
concentrated wash buffer, a europium standard solution (100 nmol/1), a glass vial of 
highly purified 7.5% (w/v) bovine serum albumin solution and a 96 well microtitre 
plate.
The manufacturer's instructions recommend that the labelling procedure be 
carried out in a different room to where the assay is performed in order to avoid 
possible contamination of work areas with europium. However, due to space 
limitations, this was not possible. Nevertheless, every care was taken to ensure that 
none of the concentrated europium label was spilt onto work surfaces and automatic 
pipettes used in the labelling procedure were not used in the assay. Europium 
contamination of the work area is difficult to detect, although as yet there appears to 
be no evidence (such as increased background counts in the assay) that contamination 
occurred during any of five labelling procedures.
Before the labelling reaction was initiated, a gel-filtration chromatography 
column containing Sephadex G-25 and Sephadex 6B was prepared. A 10 ml
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disposable plastic pipette (28 cm long with an internal diameter of 0.8 cm) held 
vertically was partially sealed at the lower end by inserting a plug of porous glass 
wool. A well mixed slurry of Sepharose 6B was poured slowly into the pipette until a 
15 cm column was formed. A suspension of Sephadex G-25 was then used to create 
an additional 7 cm of column above the Sepharose 6B. A small plastic funnel was 
attached to the top of the column to act as a fluid reservoir and a 7 cm piece of plastic 
tubing was attached to the lower tip of the column to aid dispensing of the eluant. 
Forty ml of elution buffer (see Materials and Methods) was passed through the 
column which was then sealed at each end until needed. At no time was the column 
allowed to dry out. It was possible to use the same column on several occasions 
provided it was first flushed with 50 ml of decontamination buffer (see Materials and 
Methods) followed by 50 ml of elution buffer to remove any residual europium label 
or protein.
The coupling reaction between the europium-DTTA chelate and protein is 
inhibited by compounds containing amine groups, even when they are present at very 
low concentrations (^ O^) xhe reaction mixture must therefore be free of buffers 
containing amine groups, for example, Tris and HEPES. Buffers containing sodium 
azide should also be avoided. The Binding Site anti-apo B antibody was supplied in a 
Tris/saline buffer containing 0.1% (w/v) sodium azide. A buffer exchange' procedure 
was therefore employed to separate the antibody from these undesirable compounds. 
A PD-10 Sephadex chromatography column from Pharmacia was used according to 
the manufacturer's instructions. 25 ml of europium labelling buffer (see Materials and 
Methods) was passed through the column. 0.4 ml of the anti-apo B antibody solution 
containing 6 mg of protein was pipetted onto the column followed by 2.1 ml of 
labelling buffer and 2.5 ml of eluant was collected. This was shown to be virtually 
protein-free by its lack of absorbance at 280 nm. A further 3.5 ml of labelling buffer 
was pipetted onto the column and 3.5 ml of eluant was collected. It was assumed that 
all 6 mg of protein was present in this fraction. 0.5 ml of this fraction (containing 
-0.85 mg of protein) was pipetted into the labelling vial and mixed gently. The
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remainder of the solution was stored in aliquots at -20®C to be used in subsequent 
labelling procedures.
Reaction conditions play a significant part in producing high incorporation of 
europium into protein. Examples of the effects of labelling buffer pH, and of 
incubation time and temperature on europium incorporation were supplied by the 
manufacturer and are reproduced in Figure 4.1. The manufacturer warns that 
proteins, particularly monoclonal antibodies, may be damaged by exposure to 
extremes of temperature and pH. Therefore, as a starting point, reaction conditions 
described by the manufacturers as 'mild' were used for the first labelling. These were 
: a labelling buffer pH of 8.5, and an overnight (18 hour) incubation at room 
temperature (20°C).
The entire contents of the labelling vial (i.e. labelled antibody and free label) 
was then pipetted onto the top of the Sephadex/Sepharose column. The labelling vial 
was washed with 0.5 ml of elution buffer which was also added to the column. Once 
the buffer had entered into the column 60 ml of elution buffer was poured into the 
funnel, and thirty x 2 ml fractions were collected. In subsequent labellings, forty x 0.5 
ml fractions were collected. The latter protocol improved resolution between the 
labelled antibody and free label fractions eluting from the column. The manufacturers 
recommend that the absorbance at 280 nm of the eluant should be continuously 
monitored during the separation procedure in order to identify the peak of labelled 
antibody. Since a suitable automated fraction collector was not available in this 
department the fractions were collected manually.
Fractions were mixed by vortexing and diluted to 1:10,000 in enhancement 
solution (see Materials and Methods). 200 |Xl of the diluted fractions were then 
pipetted, in duplicate, into the wells of a microtitre plate. The plate was then mixed 
gently on a plate shaker for 5 minutes before fluorescence measurements were taken 
on the time-resolved fluorimeter. A plot of fluorescence counts versus fraction 
number revealed a peak of free europium, a separate peak of monomeric labelled 
antibody and (on some separations) a peak of aggregated labelled antibody. The
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aggregate eluted from the column first, followed by monomeric labelled protein and 
then the free label. Plots for each labelling procedure are presented as figures 4.2 to 
4.7.
This protocol was considered to be adequate to identify the individual peaks 
obtained, but, as a check, the absorbance of each fraction was measured at 280 nm . A 
spectrophotometer (Cecil instruments) employing quartz cuvettes was used to read the 
absorbance of each fraction against a deionised water blank. Peaks for protein 
content corresponded to the peaks obtained for europium content (figure 4.4). Figure
4.5 also shows an additional peak (likely to be of labelled aggregated antibody) which 
elutes from the column in the first 4 ml fraction. The labelled protein elutes in the 4-8 
ml fraction and the free label elutes in the 8-18 ml fraction.
Fractions known to contain labelled monomeric antibody (those fractions 
enclosed by the arrows in figures 4.2 to 4.7) were pooled. Care was taken to ensure 
that aggregated protein was not included in the pool since such protein causes 
problems of high background and assay imprecision. Approximately 3 ml of labelled 
antibody solution was obtained from each labelling procedure.
The pooled labelled antibody was then characterised as follows according to the 
manufacturer’s instructions (226);.
67
Europium concentration.
The pooled labelled antibody was diluted 1:10,000 and the europium standard was
diluted 1:100 in enhancement solution. 200 pi of each solution was pipetted (in
quadruplicate) into a microtitre plate which was then shaken gently for five minutes
before fluorescence readings were taken. The europium content of the label was
calculated as follows:-
counts for diluted label x dilution factor (10.000) (pmol/L)
1000 X counts of 1 nmol/1 europium standard
A factor of 1000 is used to correct for the conversion of units from nmol/L to pmol/L. 
Protein concentration
The protein concentration (mg/ml) was determined from the absorbance of the pooled 
labelled antibody solution at 280 nm read against a blank of deionised water. A factor 
of 0.008 was subtracted from the absorbance for every pmol/L of europium present in 
the label to compensate for absorbance due to aromatic thiourea bonds formed during 
the labelling process.
Knowing that the absorptivity value for 1 mg/ml of IgG is 1.34, the protein
concentration was calculated as follows :-
(Absorbance at 280 nm) - fO.008 x Europium cone (pmol/Lll (mg/ml)
1.34
To estimate the labelling yield, an approximation of the molar protein concentration 
was needed. Since the molecular weight of IgG is 160 kDa, the protein concentration 
is :-
Protein concentration fmg/mll x 1.000.000 (pmol/L)
160,000
Labelling yield.
The labelling yield was calculated by dividing the europium concentration by the 
protein concentration (both in pmol/L).
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The manufacturers recommend that a labelling yield of 5-15 Eu/IgG is desirable 
although lower yields (2-5 Eu/IgG) should produce satisfactory assays. Yields in 
excess of 20 Eu/IgG may cause problems due to formation of protein aggregates.
Recovery.
An estimate of the percentage recovery of protein initially added to the labelling vial 
may be made as follows :-
Protein concentration fmg/mll x volume of solution (mil x 100 
Protein added (mg)
Following these calculations highly purified BSA was added to the labelled 
antibody pool to a final concentration of 0.1% (w/v). BSA was added as a carrier for 
the labelled protein and to minimise its adhesion to storage containers. An anti­
bacterial agent, sodium azide (0.1%), was already present in the elution buffer. The 
labelled antibody was divided into 0.5 ml aliquots and stored in plastic containers at 4 
°C. Freezing of the label is strongly discouraged by the manufacturers.
4.3 RESULTS.
Three different antibodies were labelled with europium. Two are 
commercially-available polyclonal antibodies, and the other, the monoclonal antibody 
(29c 10), was generated 'in-house' (described in Chapter 3). The characteristics of each 
labelled antibody obtained from the labelling procedures is presented in Table 4.1. 
The elution profile of each of the chromatographic separations is presented in Figures
4.2 to 4.7.
More detail on individual labelling procedures is presented below.
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4.3.1 'Binding Site' anti-apo B polyclonal antibody.
This antibody was labelled on three occasions (figs 4.2 to 4.4). The first two 
labellings used antibody that had just undergone the buffer exchange procedure while 
the third labelling used antibody that had undergone buffer exchange for labelling on 
5/10/92 and was then stored for 11 months at -20°C until use.
Only in the third labelling procedure was the protein content (determined by 
absorbance 280 nm) estimated together with the europium content. This data (shown 
in figure 4.4) confirmed that the peaks identified by estimation of europium content 
were the same as those that contained the labelled antibody.
Data in table 4.1 shows that, providing reaction conditions were kept 
reasonably constant, the europium yield remained constant. Increasing the labelling 
time (labelling 3 on 2/9/93) by 6 hours elicited a proportionate increase in europium 
incorporation (8.7-11.7 europium atoms/antibody).
4.3.2 'Immune' anti-apo (a) polyclonal antibody.
This antibody, which was labelled on a single occasion (fig 4.5), gave rise to 
the most discrete separation of fractions. In addition, a relatively large peak 
containing aggregated labelled antibody was also seen, although this peak was not 
included in the labelled antibody pool.
4.3.3 29cl0 anti-apo (a) monoclonal antibody.
This antibody was labelled on one occasion but with a slightly different 
labelling protocol: the pH of the labelling buffer was increased from 8.5 to 8.65 in an 
attempt to improve europium incorporation into the antibody. However, the resulting 
label had the lowest europium incorporation of all (figs 4.6 & 4.7)! At 0.2 Eu 
atoms/antibody, it was considered that this label would not produce a satisfactory 
assay. Surprisingly, even with such a low europium content, the label was found to 
be suitable for use in Lp(a) assays (chapter 5).
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4.4 DISCUSSION.
These results demonstrate that the labelling of antibodies with europium is a 
simple procedure requiring a minimum of specialised apparatus. There are no known 
safety hazards associated with the procedure and, providing meticulous care is taken 
to avoid contamination of work areas, the assay can be performed in the same room as 
the labelling procedure.
Since individual antibodies exhibit differing degrees of europium 
incorporation during labelling, optimisation of the reaction conditions should be 
performed for each labelled protein. Ideally each parameter of the labelling procedure 
(reaction mixture pH, temperature and incubation time) should be optimised to 
maximise labelling yield. However, the cost of the kit is a major limiting factor and 
such extreme optimisation would probably cost in excess of £1000 for each antibody. 
The relatively 'mild' labelling conditions (short incubation at low pH and 20°C) 
which were used in this project appeared to give satisfactory yields for each 
polyclonal antibody that was labelled. However, labelling yield was much lower for 
the monoclonal antibody.
The reason for the very low europium incorporation into the 29c 10 antibody is 
unclear. Since the Eu-DTTA chelate reacts with amino groups on protein, it is 
possible (although unlikely) that the 29c 10 antibody contains relatively few of these 
groups. Other possibilities include contamination of reagents with amine-containing 
compounds, or the reaction conditions used were too mild for adequate incorporation. 
Increasing the reaction mixture pH to 8.65 was very unlikely to have damaged the 
29c 10 antibody, since this antibody is stable in the bicarbonate buffer (pH 9.2) used 
for antibody coating of microtitre plates (see chapter 5).
One of the great advantages of lanthanide labels is their stability. Storage of 
labelled antibodies at 4°C in 0.5 ml aliquots is reconunended. Although no formal 
stability studies have been made there appeared to be no loss in assay performance 
when labels were stored for up to one year. As a precautionary measure, the antibody 
is passed through a 0.22pm filter before use in an assay to remove any aggregates of
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labelled antibody which occasionally form since such aggregates have been shown to 
adversely effect assay precision (data not shown).
A labelling kit using another lanthanide, samarium, is also commercially 
available. Although the intensity of emitted fluorescence from samarium is less than 
for europium, the use of antibodies labelled with either of these two lanthanides 
offers the prospect of dual-analyte assays on a single microtitre plate.
In conclusion, the labelling of antibodies with europium is an excellent 
alternative to conventional radioisotope or enzyme labelling. The cost of reagents is 
not high considering that one labelling procedure may produce sufficient antibody 
for over 100 microtitre plate assays. Importantly, there are no requirements for 
special working environments and no known safety hazards.
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FIGURE 4.2
Anti-apo B polyclonal antibody : europium labelling 1/7/92
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FIGURE 4.3
Anti-apo B polyclonal antibody : europium labelling 6/10/92
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Elution profiles for two europium labellings of an anti-apo B polyclonal antibody. 
Fractions between the arrows were pooled to make the working labelled antibody.
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FIGURE 4.6
29C10 anti-apo (a) monoclonal antibody : europium labelling 31/3/93
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FIGURE 4.7
29C10 anti-apo (a) monocional antibody ; europium labelling 31/3/93
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Figure 4.6 : an elution profile for labelling of an anti-apo (a) monoclonal antibody, 29c10. 
Figure 4.7 shows an enlargement of figure 4.6.
Fractions between the arrows were pooled to make the working label.
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CHAPTER 5
DEVELOPMENT AND OPTIMISATION 
OF A TIME-RESOLVED FLUOROIMMUNOASSAY FOR Lp(a)
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5.1 Introduction.
Optimisation of each phase of an immunoassay is essential to ensure reliable 
analytical performance. Data obtained during experiments designed to optimise each 
step of the time-resolved fluoroimmunoassay for Lp(a) are presented in this chapter. 
The following assay protocol was used (unless stated otherwise)
(i) Microtitre plates were coated with an anti-Lp(a) capture antibody.
(ii) The plates were washed to remove unbound capture antibody.
(iii) Binding sites on the wells were blocked' using a solution of bovine serum 
albumin (BSA).
(iv) Excess unbound BSA was removed by washing with a Tris/HCl wash buffer.
(v) Diluted sample was added to the well to allow binding of Lp(a) in the sample 
to the capture antibody.
(vi) The microtitre plate was washed to remove unbound diluted sample.
(vii) Europium -labelled anti-Lp(a) detection antibody was added to each well
(viii) The plates were washed to remove unbound europium-labelled antibody.
(ix) Enhancement solution was added to each well. The resulting fluorescence was 
detected and measured in each well.
Suitable incubation times were employed for each of the steps.
5.2 Coating of microtitre plates with antibody.
5.2.1 Introduction.
Development of a two-site microtitre plate-based immunoassay requires one 
of the antibodies to inunobilised on the plate. This may be achieved by a variety of 
methods (^ 7^) The simplest involves a process whereby the antibody, in alkaline 
solution, passively adsorbs to the plastic microtitre well. The technique does not 
entail the formation of any chemical bonds and results in little damage to the protein 
structure (^ 27) The process is sometimes known as 'passive diffusion' Most 
assays using this method of microtitre plate coating involve dilution of the antibody in 
bicarbonate buffer (pH~9.0) and overnight incubation at 4®C.
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Development of an assay for Lp(a) presented a theoretical problem of 
specificity: since the plate coating (capture) antibody was exposed to serum 
containing apo B (present in particles other than Lp(a)) (228) as well as apo (a) (present 
only in Lp(a)) the use of an anti-apo B antibody to capture Lp(a) might allow 
competition for antibody binding sites between apo B present in Lp(a) and apo B 
present in the other serum lipoprotein particles. In contrast, the use of an anti-apo (a) 
capture antibody would present no competition problems because apo (a) is present 
only in Lp(a) (33). For this reason it was decided to use an anti-apo (a) capture 
antibody. Three anti-apo (a) antibodies were available: a commercial polyclonal 
antibody from Tmmuno' and two monoclonal antibodies (29c 10 and 35f5) which 
were produced in-house. The performance of each of these as capture antibodies was 
investigated.
5.2.2 Optimising the antibody coating of microtitre plates.
(i) Choice of antibody dilution.
Each antibody was diluted in bicarbonate buffer (pH 9.2) to produce a range 
of concentrations which were used to coat microtitre plates (250p.l of each solution 
per well overnight at 4°C). For each antibody, a serum sample containing an elevated 
concentration of Lp(a) (-800 mg/L) was assayed using the standard protocol 
described above. A plot of fluorescence counts versus antibody dilution was used to 
determine optimal antibody dilution (i.e. the antibody dilution at which small changes 
in dilution had little effect on the number of fluorescence counts).
Immuno’ anti-apo (a) polyclonal antibody (-6  mg/ml) was diluted 1:250 in 
bicarbonate buffer and serially diluted 1:2 to give a final dilution of 1:32000. These 
solutions were then used to coat microtitre plates. A steady increase in fluorescence 
counts was observed with decreasing antibody dilution (figure 5.1). This suggests 
that maximum binding of capture antibody to the microtitre plate did not occur with
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the antibody dilutions used. A (sub-optimal) dilution of 1:250 was chosen to coat 
subsequent plates in order to conserve antibody stocks.
35f5 antibody was diluted directly from the ascitic fluid (without purification) to 
1:125 - 1:16000 and used to coat microtitre plates. Since the antibody concentration 
of the ascitic fluid was not known, it was not possible to calculate the amount of 
antibody added per well.
The plot of fluorescence counts versus antibody dilution are shown in figure 
5.2. Unexpectedly, fluorescence counts were lower at both high and low dilutions of 
the antibody. The reduction of counts at high antibody dilution may have resulted 
from the antibody being present in limiting amount (i.e. fewer antibody molecules 
coating the plate than Lp(a) molecules present in the sample). However, the reason 
for the decrease in fluorescence counts at low antibody dilution is less clear. Possibly 
the presence of relatively large quantities of other proteins (such as albumin) in the 
ascitic fluid may block the non-specific adsorption of the antibody to the plastic 
microtitre plate. To eliminate experimental error the experiment was repeated on a 
further two occasions with identical results. A dilution of 1:1000 was chosen for assay 
development, this value being at the plateau of the plot (figure 5.2).
29cl0 antibody (7.2 mg/ml - purified by hydroxy apatite adsorption chromatography) 
was diluted 1:125 and serially diluted 1:2 to give a final dilution of 1:4000: these 
dilutions were used to coat microtitre plates. Fluorescence counts at each antibody 
dilution are shown in figure 5.3. It is apparent that a 1:1000 antibody dilution 
(although slightly sub-optimal) would be suitable for assay development because 
small changes in antibody dilution have little effect on fluorescence counts.
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(ii) Plate coating incubation time.
Antibody coating of microtitre plates is usually performed during overnight 
incubation at 4®C (^ 27) An experiment was performed to determine the minimum 
time necessary to achieve adequate coating with anti-apo (a) antisera without 
deterioration in assay performance. Microtitre plates were coated either overnight at 
4°C or 1 hour at 20°C. To assess the efficiency of the antibody coating, a series of 
Lp(a) standards were analysed using the standard assay protocol. The standard curves 
thus obtained are shown in figure 5.4, There appears to be little difference between 
the curves obtained at each temperature, suggesting that microtitre plate coating with 
this antibody was complete within one hour. An experiment using incubation times 
of less than one hour at 20°C suggested that antibody coating was virtually complete 
after 20 minutes (data not shown). The microtitre plate coating properties of the 
monoclonal antibodies, 29c 10 and 35f5 were also investigated: the data obtained (not 
shown) verified that a 1 hour incubation at 20°C was sufficient for optimal antibody 
coating of microtitre plates. It was decided that 1 hour would be the minimum time 
used for antibody coating since shorter incubation times might lead to inconsistent 
coating, thereby causing imprecision in the assay.
(iii) Re-use of coating solution.
Reports suggest (227) that only a small proportion of the antibody in coating 
solutions actually binds to the plastic of the microtitre plates. It would be wasteful to 
discard the antibody solution following its incubation with the microtitre plates. 
Indeed, in principle there is no objection to the re-use of this solution to coat 
additional plates. Plates were coated with each of the three anti-apo (a) antibodies at 
their optimal dilutions. After coating, the solutions were collected and used to coat 
another microtitre plate. This procedure was repeated up to 10 times. Approximately 
95% of the antibody coating solutions was recycled and used for the next coating 
procedure; the solutions were stored at 4°C when not in use. A series of Lp(a) 
standards were assayed using microtitre plates coated either with freshly diluted
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antibody or with 'recycled' antibody solution (of the same initial antibody 
concentration) that had already been used to coat 10 microtitre plates. Standard 
curves produced using microtitre plates coated with each of the three anti-apo (a) 
antibodies are shown in figures 5.5 - 5.7. It is apparent that there are only slight 
differences in each pair of curves. Hence, as it is highly unlikely that these slight 
changes would significantly affect assay performance, antibody solutions were re­
used for up to ten occasions throughout this study.
(iv) Stability and storage of coated plates.
One of the major variables in the performance of microtitre plate assays is 
inconsistent coating of antibody to the plate (229) This variability may be minimised 
by preparing a large batch of microtitre plates (using the same coating antibody 
solution) to be stored prior to subsequent use. Microtitre plates were coated with 
antibody, blocked with BSA (section 5.3) and stored desiccated for up to 90 days at 
4°C. After storage, the efficiency of the antibody coating was assessed by analysing a 
series of Lp(a) standards using the stored plates and comparing the results with those 
obtained using plates freshly coated with antibody. The standard curves thus obtained 
(not shown) were virtually superimposable, suggesting that antibody coated microtitre 
plates may be stored for three months at 4°C with no loss in assay performance. 
However, when an antibody coated plate was. stored for six months under these 
conditions some loss in performance, particularly precision of duplicates, was seen 
(data not shown).
Each of the antibodies were found to be stable when used to coat microtitre 
plates. However, when a series of Lp(a) standards were analysed on microtitre plates 
coated with each of the three antibodies at their 'optimum' conditions (figure 5.8) it is 
apparent that the most linear dose-response curve and highest fluorescence counts 
were obtained using plates coated with 29c 10. Therefore, the 29c 10 antibody was the 
most suitable for coating microtitre plates.
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5.3 Blocking of non-specific binding sites.
Most microtitre plate assays use bovine serum albumin (BSA) to occupy 
('block') sites on the microtitre plate wells that might otherwise bind assay reagents 
non-specifically (i.e. at low affinity) (230)^  in a two-site immunoassay, non-specific 
binding is expressed as the signal obtained for the zero standard, which should 
(ideally) be close to zero. A low and precise signal for the zero standard is essential 
for good assay sensitivity (231). A 400 g/L solution of BSA was prepared in PBS, 
stored at 4°C, and diluted for use as required.
5.3.1 Volume of 'blocking' solution.
It is standard procedure that the volume of BSA solution used to block 
microtitre plate wells should exceed the largest reaction volume used (230), For 
instance, a reaction volume of 200pJ requires a minimum blocking volume of SOOpJ, 
particularly if the reaction mixture is to be shaken during incubation (the vortex thus 
created causing liquid to rise to a higher level in the wells than when at rest). The 
effect of using different volumes of blocking solution was investigated using 
microtitre plate wells coated with 29c 10 antibody which were 'blocked' with either 
100,250, 300 or 400pl of BSA solution (1% w/v). The plate was blocked' for 1 hour 
at 20°C and, after washing away unbound BSA, fifteen replicates of an Lp(a) zero 
standard (assay buffer) were assayed for each volume of BSA. The mean and 
standard deviation (SD) of the fluorescence counts for these wells (presented in table 
5.1) give an indication of the efficiency of the 'blocking' : a low mean and SD 
reflecting efficient blocking.
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Table 5.1.
Mean/Standard deviation fluorescence counts for 15 replicates of a Lp(a) zero 
standard assayed using the 29clO-B time-resolved fluorescence Lp(a) assay on 
microtitre plates 'blocked' with 100-400 |xl BSA (1% w/v)
Vo]ume of 1% (w/v) BSA
Fluorescence lOOpI 250pl 300pl 400pl
counts
mean 8579 3105 1536 1570
SD 6542 356 85 102
It is apparent that blocking with a low volume of BSA is inadequate since very high 
and imprecise fluorescence readings are obtained. At least 300pl of BSA is required 
for efficient blocking. The fact that 250|xl of BSA is insufficient for complete 
blocking of the plate suggests that a reaction volume of 200pJ rises during shaking 
above the level occupied by 250|xl of solution at rest. 300pl of 1% (w/v) BSA 
solution was therefore used during assay development.
5.3.2 Concentration of 'blocking* solution.
1% (w/v) BSA is commonly employed as a plate blocking agent in 
immunoassays (230), Microtitre plates blocked' with this solution were compared with 
those blocked' with a more concentrated (5% w/v) solution to determine whether 
'blocking' efficiency could be improved. Fifteen replicates of zero standard were 
assayed using a 29c 10 coated microtitre plate that had been 'blocked' with 300pl of 
either 1 or 5% (w/v) BSA for 1 hour at 20°C. The mean and SD of the fluorescence 
counts are presented in table 5.2.
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Table 5.2.
Mean/Standard deviation fluorescence counts for 15 replicates of a Lp(a) zero 
standard assayed using the 29clO-B time-resolved fluorescence Lp(a) assay on 
microtitre plates 'blocked' with 300 pi BSA (1 or 5 % w/v)
BSA concentration (% w/v)
Fluorescence counts 1 5
mean 1536 1596
standard deviation 85 83
It is apparent that increasing the concentration of BSA has little effect on precision or 
number of counts for the zero standard.
Increasing BSA blocking times from 1 hour at 20°C up to 5 days at 4°C was shown 
to had no adverse effects on Lp(a) assay performance (data not shown).
5.4 Washing of microtitre plates.
Adequate washing of microtitre plate-based immunoassays is essential for 
good precision and low background counts (232), in this study, microtitre plates were 
washed with a diluted Tris-HCl buffer supplied with commercial DBLFIA® kits. 
Washing was performed using a DELFIA® automated plate washer. Up to 9 wash 
cycles (each dispensing 400pl of wash buffer) are possible using this instrument, and 
after the final wash cycle the plate is aspirated to near-dryness.
A suitable number of wash cycles were arbitrarily selected for each step of the 
Lp(a)assay as follows:
Wash following coating of microtitre plate with antibody . 3 cycles
Wash following BSA blocking' of microtitre plate. 1 cycle
Wash following incubation with diluted sample. 4 cycles
Wash following incubation with labelled antibody. 6 cycles
To assess the efficiency of the washing, europium labelled antibody was 
added to 16 wells 'blocked' with BSA. It was estimated that the europium added to
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each well would produce -170,000,000 fluorescence counts. The plate was washed 
for 6 cycles after the addition of labelled antibody and the fluorescence remaining in 
the wells measured. Using this procedure, less than 2000 counts remained in each 
well, which represented 0.001% of the total counts added. The selected washing 
procedure is therefore highly efficient.
5.5 Optimising the assay protocol.
In immunoassays the incubation of sample analyte with capture and detection 
antibodies may be performed either as a single step (in which sample, capture and 
detection antibodies are incubated together) or in two sequential steps (in which, 
following incubation of the sample with capture antibody, unbound sample is 
removed by washing and detection antibody is then added) (233)
Of the four antibodies suitable for use in the Lp(a) assay, three are directed 
against epitopes on apo (a), and the other to an epitope on apo B. The anti-apo B 
antibody and two of the anti-apo (a) antibodies were labelled with europium. For the 
reasons discussed in section 5.2.1 it was decided that the anti-apo B antibody could 
not be used to coat the plate. Therefore, assays were developed using this antibody as 
a detection antibody after Lp(a) was immobilised using an anti-apo (a) antibody. This 
antibody combination ensured that interference from other apo B-containing 
lipoproteins in human serum and from plasminogen was eliminated. The use of an 
anti-apo (a) antibody to capture Lp(a) minimised potential effects of variable binding 
of the different Lp(a) isoforms. It is likely that these effects would be greater when 
Lp(a) bound to a detection antibody rather than a capture antibody for the following 
reasons: the Lp(a) particle needs only to be bound at one site on a capture antibody to 
become immobilised on a microtitre plate, therefore, binding at more than one site 
(i.e. if the capture antibody recognises the kringle 4 repeat domain of Lp(a)) should 
not increase the amount of Lp(a) bound to the microtitre plate. However, if the 
binding of the detection antibody is influenced by isoform size, then for one isoform
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(of low molecular weight) it may be that only one labelled antibody molecule will 
bind while for another isoform (of high molecular weight) more than one labelled 
antibody may bind. This effect would obviously lead to spurious assay results.
5.5.1 Assays using an anti-apolipoprotein B detection antibody; (a)-B; 29clO-B; 
35f5-B.
A series of Lp(a) standards (diluted 1:500) were assayed using anti-apo (a) 
coated microtitre plates employing either a two-step or a one-step protocol. Equal 
concentrations of sample and detection antibody were used in each case and the total 
incubation time of each assay was identical (5 hours at 20°C).
Figure 5.9 shows the standard curves obtained using each protocol, the one- 
step assay produces a sharp increase in fluorescence counts (compared with the two- 
step protocol) at low analyte concentrations which then decreases at higher Lp(a) 
concentrations. In contrast, the two-step assay produces a steady increase in 
fluorescence counts with increasing analyte concentration across the assay range. A 
repeat of this experiment using a 1:3000 dilution of the Lp(a) standard produced 
similarly shaped standard curves (data not shown). The non-linearity encountered in 
the one-step assay may be attributed to the presence of other apo B-containing 
proteins in the Lp(a) standard (which is derived from pooled human serum). These 
proteins, present in greater quantity than Lp(a) is in normal serum (1-2 g/L), may 
compete with Lp(a) for the europium labelled anti-apo B detection antibody. In the 
Lp(a) standard at 1:500 dilution there is a high concentration of non-Lp(a), apo B- 
containing proteins, relative to Lp(a). Therefore, the majority of labelled antibody is 
bound to these proteins in preference to Lp(a). Consequently, the fluorescence counts 
for standards with a high Lp(a) concentration are reduced. However, when the 
standard was diluted further (to 100 mg/L) the total concentration of apo B-containing 
proteins was considerably lower and competition between apo B in Lp(a) and other 
proteins for the labelled antibody is minimised. The addition of higher concentrations
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of labelled antibody to the one-step assay improved linearity, but also increased non­
specific binding (data not shown).
5.5.2 Assays using anti-apolipoprotein (a) detection antibodies.
In principle, the use of an anti-apo (a) detection antibody to both capture and 
detect Lp(a) should eliminate problems due to the presence of apo B in serum 
samples. However, the structural homology of apo (a) with plasminogen may cause 
problems of specificity. These possibilities were tested using a series of one- and two- 
step assays.
(i) One-step (a)-(a) assay.
Microtitre plates were coated with a polyclonal anti-apo (a) antibody 
(Immuno) and lOOjil of a series of Lp(a) standards (diluted 1:500) were pipetted, 
together with lOOpl of europium-labelled anti-apo (a) detection antibody, into each 
well in a one-step procedure. This reaction mixture was incubated for three hours at 
20°C and the assay completed using the standard protocol. Figure 5.10 shows the 
standard curve obtained using this procedure which reaches a plateau at high Lp(a) 
concentrations. Although increased sample dilution improved the linearity of the 
standard curve (data not shown), the theoretical problem of specificity resulting from 
use of the same antibody to both capture and detect Lp(a) precluded its further use.
(ii) One- and two- step 35f5-(a) or 29cl0-(a) assays.
The data presented in this section was obtained using the 35f5-(a) assay. The 
29cl0-(a) assay was shown to perform in a similar way (data not shown). A 
comparison of one-, versus two-step assays using a final sample dilution of 1:4000 
and labelled antibody diluted at 1:1000 was undertaken. The one-step assay was 
incubated for six hours while the two-step assay had two 3 hour incubations. All 
incubations were at 20°C. Figure 5.11 shows standard curves produced using each
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assay format. It is apparent that both assays generate essentially linear standard 
curves with the one-step assay giving slightly higher fluorescence counts.
The performance of these assays at very high Lp(a) concentrations was 
investigated in an attempt to determine the concentration at which any high-dose 
hook effect' (234) might occur. The Lp(a) standard was diluted 1:10 to give a Lp(a) 
concentration well above the highest seen in human serum, and serially diluted to 
1:1000. These dilutions were analysed using one- and two-step assays.
Figure 5.12 demonstrates that at very high analyte concentrations the one-step 
assay shows a 'hook' while the two-step assay does not. The arrow on the graph 
represents the Lp(a) concentration corresponding to a 1600 mg/L standard assayed 
using 200pJ of a 1:4000 sample dilution. From this data it appears that no linearity 
problems would be encountered with either assay format at the Lp(a) concentrations 
seen in human serum (up to -2000 mg/L). However, it was decided to abandon the 
one-step assay in favour of the two-step due to the better precision of the latter.
(Hi) One- and two-step 35f5-29cl0 assays.
In spite of the low europium incorporation into the 29c 10 antibody (0.23 
Eu/antibody) (section 4.3.3), viable assays were developed. Microtitre plates were 
coated with 35f5 and one- and two-step assays were performed using a final sample 
dilution of 1:500 and a labelled antibody dilution of 1:1000. Two incubations each of 
2 hours were used for the two-step assay and a single 4 hour incubation was used for 
the one-step procedure. The resulting standard curves (presented in figure 5.13) were 
very similar, therefore either assay was suitable for quantitation of Lp(a).
(iv) 29cl0-29cl0 two-step assay.
A two-step assay was designed using the 29c 10 antibody to both capture and 
detect Lp(a). A series of Lp(a) standards (diluted 1:500) were assayed using 
microtitre plates coated with 29c 10 and a 1:1000 dilution of europium-labelled 29c 10.
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However, although theory suggests that two identical monoclonal antibodies should 
not be able to bind at the same site on an antigen, this antibody combination did 
generate a standard curve for Lp(a) (figure 5.14) : indeed the fluorescence counts for 
the Lp(a) standards were similar to those produced using the 35f5-29clO assay (figure 
5.13). The data in figure 5.14 suggests that the 29c 10 monoclonal antibody was able 
to bind to more than one site on the Lp(a) particle, probably to the kringle 4 domain 
(of which there are between 5-37 copies per Lp(a) particle). A detection antibody 
directed against this domain would be unsuitable for use in the Lp(a) assay since its 
binding to Lp(a) isoforms would be influenced by the number of kringle 4 repeat 
domains present in the isoform.
(v) B-29cl0 two-step assay.
Although it was recognised that this antibody combination might present a 
problem of competition between apo B present in Lp(a) and apo B in other 
lipoproteins (for capture antibody binding sites), a two-step assay was, nevertheless, 
developed and a linear standard curve was obtained (data not shown).
In summary, the choice of assay format was found to be highly dependant 
upon the antibody combination to be used. Assays employing two anti-apo (a) 
antibodies performed equally well in both the one- and two-step protocols. However, 
when using an anti-apo B detection antibody it was essential to employ a two-step 
format to avoid competition between apo B in Lp(a) and apo B present in other 
lipoproteins for binding to the detection antibody. Overall, each of the antibody 
combinations produced reasonably linear standard curve particularly when a two-step 
assay was used. A two-step assay using the 29clO-B antibody combination was 
selected to quantitate Lp(a) in patient samples since this combination was considered 
less likely to be influenced by size variations between the Lp(a) isoforms.
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5.6 Sample dilution.
It was apparent that serum samples would require dilution before analysis on 
the time-resolved fluorescence assay since commercial ELISA and IRMA kit assays 
use 1:42 to 1:500 predilution of samples prior to analysis. A 1:1000 sample dilution 
was chosen for the 29clO-B antibody combination as this produced a near-linear 
increase in fluorescence counts with increase in analyte concentration.
Because a large sample dilution was employed, it was possible to change the 
dilution factor of serum samples (without changing the dilution factor of the standard) 
in order to extend the sensitivity of assay further. For instance, a sample containing 
Lp(a) at less than 1 mg/L in an assay using a 1:1000 dilution may be reassayed at a 
1:100 dilution and the result obtained divided by 10 to give a more accurate 
estimation of concentration.
5.7 Optimisation of europium-labelled antibody concentration.
The labelled (detection) antibody in a two-site immunoassay is usually present 
in excess so that all of the molecules bound by the capture antibody are detected by 
the labelled antibody (^ 4^) One important consideration when optimising the detection 
antibody concentration is that increasing additions of labelled antibody tend to 
increase non-specific binding (NSB). Low NSB is essential for a sensitive assay (see 
section 6.3.1).
Method
In the following experiments, two-step assays were used. Lp(a) standard (800 
mg/L at 1:1000 dilution) was incubated for 3 hours at 20°C using a 35f5 coated 
microtitre plate. After washing, 200pl of europium-labelled antibody (at various 
dilutions) were pipetted into each well and incubated for two hours at 20°C. The 
assay was then completed using the standard protocol.
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5.7.1 Anti-apolipoprotein B detection antibody.
A series of dilutions of the concentrated labelled antibody solution were made 
(1:1000 to 1:25) giving a range of concentrations from 31 to 1224 ng per well. Figure 
5.15 plots fluorescence counts for the 800 mg/L Lp(a) standard versus amount of 
labelled antibody/well. It may be seen that a significant increase in fluorescence 
counts was achieved by increasing the amount of label added. The fluorescence 
counts for the zero standard increased from 800 for the 1:1000 labelled antibody 
dilution to 13500 for the 1:25 dilution. It appears that even at a 1:25 dilution an 
optimal labelled antibody concentration was not achieved. For subsequent assays the 
label was diluted to 1:1000 because at this concentration :-
(i) A linear standard curve was obtained.
(ii) Low and precise counts were obtained for the zero standard - thus improving 
assay sensitivity. Precision of fluorescence counts for the zero standard 
decreased as more label was added.
(iii) There was a significant saving in labelled antibody : at a 1:1000 dilution the 
antibody from one labelling procedure would be sufficient for at least 170 
microtitre plate assays whereas at 1:25 dilution only 4 assays could be run.
The reason that a true optimum label concentration was not established may 
be due to the nature of the Lp(a) particle. It is possible that more than one of the 
labelled polyclonal antibodies may bind to the relatively large apo B region of Lp(a). 
Therefore, by increasing the labelled antibody concentration, more labelled antibody 
may bind to apo B. Eventually saturation may be reached, although this appears to be 
at a very high labelled antibody concentration.
5.7.2 Anti-apolipoprotein (a) detection antibody.
Figure 5.16 shows a series of Lp(a) standard curves obtained using the anti- 
apo (a) labelled antibody at dilutions of 1:1000 to 1:250 (23.5 to 94 ng/well). 
Fluorescence counts for the zero standard increased from 1800 to 5500 at these
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dilutions. For the reasons stated for the apo B detection antibody (section 5.7.1), the 
apo (a) detection antibody was used at 1:1000 dilution.
However, as with the anti-apo B antibody, an optimum dilution was not 
achieved. Like apo B, apo (a) is a large protein and it may therefore be possible for 
more than one labelled antibody to bind to it, especially if the antibody recognises 
epitopes on the kringle 4 domain which is present in multiple copies in Lp(a). It is 
likely that both of the europium labelled antibodies ('Immuno' anti-apo (a) and 29c 10) 
bind to this domain, which makes them unsuitable for use as detection antibodies (as 
previously discussed - section 5.5).
5.8 Effect of microtitre plate agitation during incubations.
The effect of continuous shaking of the microtitre plate during incubations 
was investigated. Two sets of Lp(a) standards were analysed using 29clO-B assays; 
one plate was shaken continuously on a DELFIA® 1296-001 plateshaker, set at slow 
speed (approximately 80 vibrations/minute) and the other was left undisturbed. 
Figure 5.17 shows that a significant increase in fluorescence counts was achieved by 
continuously shaking microtitre plates during incubations presumably because the 
agitation increased the probability of antibody-antigen interactions. Continuous 
shaking of microtitre plates during incubations was used throughout assay 
development.
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5.9 Optimisation of incubation times.
One of the aims of this project was to develop an assay that could be 
completed within one (8-hour) working day. Therefore, since it was necessary to use 
a two-step assay, incubations had to be as short as possible.
5.9.1 Sample incubation
A series of Lp(a) standards (diluted 1:1000) were assayed on 35f5 coated 
microtitre plates using a two-step procedure. The diluted standards were incubated for 
1-3 hours at 20°C or overnight at 4°C. The amount of standard bound to the plate was 
quantified using a 2 hour incubation at 20°C with the anti-apo B detection antibody. 
Drat from the standard curves (figure 5.18) suggests that binding of Lp(a) to the 35f5 
capture antibody was incomplete even at three hours.
5.9.2 Labelled antibody incubation.
Three sets of diluted Lp(a) standards were assayed using 35f5 coated 
microtitre plates. Following washing, the assay was completed by addition of 200pl 
of europium labelled anti-apo B detection antibody to each well which was incubated 
for either 2,3 or 4 hours at 20®C. The binding of this anti-apo B detection antibody to 
the captured Lp(a) was time-dependant (figure 5.19), niaximum binding was not 
reached at 4 hours.
A compromise of a sample incubation time of 3 hours together with a 2 hour 
labelled antibody incubation time was subsequently employed. These sub-optimal 
incubation periods may possibly lead to problems of assay drift (gradual changes in 
results throughout an assay due to samples at the beginning and end a batch being 
incubated for slightly different times). This possibility was assessed by analysing 
serum samples both at the start and at the end of each batch. Comparison of results for 
these samples showed no consistent upwards or downwards trend, which suggests that 
systematic assay drift did not occur.
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5.10 Standardisation and quality control.
Since Lp(a) assays are seldom performed in the United Kingdom, a wide 
selection of different commercial calibrants and quality control materials are not 
readily available. The following materials were used as calibrants and quality 
controls in the time-resolved fluoroimmunoassay of Lp(a).
5.10.1 Standardisation.
A commercial preparation from 'Immuno’ was used in this project (see 
materials and methods section). Analysis of three different batches of standards (each 
with an assigned Lp(a) concentration) in one 29clO-B assay showed between-batch 
variability of up to 20% (data not shown). The manufacturers quote that the standard 
was prepared from pooled human plasma and calibrated by comparison with purified 
Lp(a) using an electroinununodiffusion technique (235)_ Since the standard was said to 
contain a mixture of S2 and S3 isoforms, the between-batch variability observed may 
be due to each standard preparation containing different proportions of these 
isoforms. This inter-standard variability has serious implications when long term 
studies employing Lp(a) assays are performed using more than one batch of standard.
The Lp(a) standards had concentrations between 680-850 mg/L. Since a small 
proportion of patients have serum Lp(a) concentrations above 850 mg/L they would 
require reanalysis after predilution. To extend the working range of the assay, the 
standard was therefore diluted half as much as the unknowns (i.e. 1:500 in an assay 
where the unknowns were diluted 1:1000) to effectively double the standard 
concentration.
5.10.2 Quality control.
No specific quality control materials are available commercially. A series of 
clinical chemistry control materials were therefore analysed in the hope of identifying 
some with suitable concentrations of Lp(a). However, many were animal serum- 
based preparations which contain no Lp(a), and those human serum preparations that
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did contain Lp(a) had concentrations below 200 mg/L. Ideally, for Lp(a) assays a 
series of controls with concentrations of approximately 50, 300 and 600 mg/L would 
be required. In order to obtain controls with these Lp(a) concentrations, serum was 
obtained from the National Blood Transfusion Service (Cambridge) which had been 
screened for Hepatitis A and B and HIV virus. After measurement of Lp(a), suitable 
samples were divided into 30|il aliquots, frozen at -20°C, and analysed in each Lp(a) 
assay to ensure the quality of the results.
5.11 Assay costings.
An important parameter in the assessment of an assay kit or newly developed 
method in today's routine Clinical Chemistry laboratory is cost. The following assay 
costings are compared to one of the more conunonly used ELISA inununoassays, the 
Inununo Immunozym® Lp(a) kit which costs £215.00. This kit has sufficient materials 
to analyse up to a maximum of 36 patient samples in duplicate, making a reagent cost 
of £5.97 per sample.
The cost of the time resolved fluorescence assay per assay (with samples analysed in 
duplicate) may be estimated as follows
Microtitre plate £ 0.50
BSA for plate blocking. (£284.60/100 g)
0.25g used/plate £ 0.71
Lp(a) standard (£23.00 for 0.5 ml)
Sufficient for 15 assays therefore cost/assay £ 1.53
Binding site anti-apo B antibody (£35/ml)
0.6 ml may be used for each labelling. £21.00/labelling
Europium Labelling kit £146 (with 20% discount )
Therefore antibody + labelling kit costs £167.00
This should produce sufficient labelled antibody for 150
assays at least. Therefore cost per assay £ 1.11
total £ 3.85
Other consumables :-Sample tubes, pipette tips.
Buffers (assay,wash, enhancement solution supplied in excess with conunercial kits).
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Chromatography materials for labelled antibody preparation,
Preparation of the monoclonal antibodies (difficult to cost).
The total cost of these per assay should not exceed £5.00.
Therefore 36 samples may be analysed in duplicate, at a cost of no more than £8.85, 
giving a cost of £0.25 per patient sample.
As the staff time required to perform both assays is similar this represents a 
considerable saving on the commercial kit assays
5.12 DISCUSSION.
The findings presented in this chapter emphasise the need for careful 
optimisation of immunoassays. Time-resolved fluorescence immunoassays for Lp(a) 
present some particular analytical problems, in that the antibodies used dictate, to 
some extent, the assay design. In retrospect, a monoclonal anti-apo (a) capture 
antibody (directed against an epitope other than the kringle 4 domain) together with a 
monoclonal anti-apo B detection antibody might be the most suitable antibody 
combination.
It was hoped that the use of a monoclonal anti-apo(a) capture antibody 
directed against the kringle 4 domain of Lp(a) would not have different affinities for 
the various Lp(a) isoforms. This may only be verified by analysing at a series of 
samples with known isoforms using various anti-apo (a) capture antibodies. A 
satisfactory electrophoretic method for isoform determination has not yet been 
completed by the author in-house, although several immunoblotting methods have 
recently been described (38,236)
Commercial ELISA assay kits use assay protocols similar to the those for the 
time-resolved fluorescence assay described here. Thus, assays using an anti-apo (a) 
antibody to both capture and detect Lp(a) use a one-step incubation, while those using 
an anti-apo (a) capture antibody with an anti-apo B detection antibody use a two-step 
procedure. Sample dilutions vary from kit to kit (1:42 - 1:500) but are in the same 
region as the time-resolved fluorescence assays. Since the commercial assay kits are 
supplied with the microtitre plate already coated with antibody and blocked with
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BSA, details of these procedures are not available. Incubation times for the ELISA 
assays are shorter than the time-resolved fluorescence assay, possibly because both 
sample and labelled antibody incubation times have not been optimised. Personal 
experience with the Immunozym® ELIS A assay indicates that 'drift* (section 5.9.2) 
occurs across the microtitre plate, this may be due to the short incubation times or to 
temperature variations across the plate which affect enzyme activity. The time- 
resolved fluorescence assay is performed at room temperature and, because it does not 
employ any enzymes, is less sensitive to temperature variations.
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Appendix 5.1
Assay protocol for a time-resolved fluorescence Lp(a) assay using a monoclonal 
anti-apolipoprotein (a) capture antibody (29cl0) and a europium labelled 
polyclonal anti-apolipoprotein B detection antibody.
Coating of microtitre plates with antibodv.
Dilute 29cl0 antibody 1:1000 in bicarbonate buffer pH 9.2, mix well. Pipette 
250pJ of solution into each microtitre plate well. Cover and incubate at 4®C overnight 
(or 1 hour at 20®C)
Empty the wells (save the antibody solution) and wash the plate 3 times with 
wash buffer using the DELFIA® automated plate washer (400jLil wash buffer/wash).
Pipette 300pl of bovine serum albumin solution (lOg/L in phosphate buffered 
saline) into each well, incubate at 20°C for 1 hour.
Wash microtitre plate once on the automated plate washer (400pl wash 
buffer/wash). The plate is now ready for use. It may be stored at 4®C in a closed, 
desiccated container for up to three months if required.
Sample preparation/application.
Dilute Lp(a) standard (current lot number 110/170 (680 mg/L)) in DELFIA® 
assay buffer. A 1:500 dilution of the standard is equivalent to 1360 mg/L in an assay 
where samples and quality control materials are diluted 1:1000. Serially dilute the 
1360 mg/L standard (1:2) in assay buffer to give a series of standards with Lp(a) 
concentrations of 680, 340, 170, 85,42.5, 21.2, 10.6 mg/L. Assay buffer is used as a 
zero standard.
Thaw, mix and centrifuge patient samples and quality control materials, dilute 
1:1000 in DELFIA® assay buffer.
Pipette 200|Lll of diluted standards, quality controls and patient samples in 
duplicate to the microtitre plate. Quality control materials should be included both 
before the first and after the last patient sample.
I l l
Incubate the microtitre plate for three hours at 20°C (with Slow shaking on the 
DELFIA® plate shaker).
Wash the plate four times on the automated plate washer (400pl wash buffer/wash). 
Add 200p,l of europium-labelled anti-apolipoprotein B antibody (diluted 1:1000 in 
DELFIA® assay buffer) to each well.
Incubate the plate for two hours at 20°C (with slow shaking on the DELFIA®plate 
shaker).
Wash the plate six times on the automated plate washer (400pl wash buffer/wash). 
Add 200p,l of DELFIA® Enhancement solution to each well.
Incubate the plate for ten minutes at 20°C with shaking on the DELFIA® plate shaker. 
Allow to stand for 5 minutes before reading.
Read the plate on the DELFIA® research fluorimeter.
Use Pharmacia Multicalc software to produce a standard curve and to calculate 
unknowns from the fluorescence counts.
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CHAPTER 6
PERFORMANCE CHARACTERISTICS 
OF THE TIME-RESOLVED FLUORESCENCE Lp(a) ASSAY
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6.1 INTRODUCTION.
Careful optimisation of each incubation step in an immunoassay (as described 
in chapter 5) should produce an assay with acceptable analytical performance. The 
assay should also be robust so that it may be performed by many different operators 
without loss of performance, and stable so that satisfactory analytical performance 
may be sustained over many years.
One aim of this project was to produce a simple, reliable and cheap assay that 
outperformed any commercial kit currently available in the United Kingdom with 
regard to sensitivity, assay range and reproducibility. It was hoped that this improved 
sensitivity would allow quantitative measurement of serum Lp(a) in all human 
subjects, where, in some previous studies none was detected
At the outset of this project targets were set for analytical performance of the 
assay, it was hoped that sensitivity below 5 mg/L with an assay working range up to 
1000 mg/L might be achieved. This would ensure that Lp(a) could be measured in 
all serum samples without any additional pre-dilution steps. The assay should be 
precise enough to produce within-batch precision less than 6% and between-batch 
precision less than 10% across the working range of the assay (237) The assay should 
be easy to perform within a working day, it should require a small sample volume and 
it should be free from interferences from other biomolecules present in human serum 
(both in health and disease). The results obtained using the assay should not be 
grossly different from those obtained using other commercially-available assay kits.
6.2 PRECISION.
Within-batch precision was estimated by analysing patient serum samples with 
high, medium and low concentrations of Lp(a) (-600,300 & 100 mg/L). Each sample 
was diluted according to the assay protocol and analysed, in duplicate, up to 12 times 
on one microtitre plate. The average value of the duplicate was then used to calculate 
the mean and standard deviation (SD) for each set of samples.
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These figures were then used to calculate the coefficient of variation (CV) of
the results using the equation (238);_ CV= SD x 100. (%)
mean
Between-batch precision was assessed using three serum samples with high, 
medium and low concentrations of Lp(a) (as above). Samples were divided into 
aliquots and frozen at -20°C. The samples were analysed in 20 separate assays. A 
fresh aliquot of each sample was thawed, mixed and centrifuged for each assay. The 
samples were analysed, in duplicate, and the mean value was recorded. The mean and 
SD of these concentrations were then used to calculate between-batch CV as above. 
These samples were used as internal quality control materials for the Lp(a) assay as 
commercial quality control preparations with suitable levels of Lp(a) are not readily 
available.
A precision profile was used to assess precision across the working range of 
the assay. The precision profile was calculated using data from Lp(a) assays and 
therefore requires no extra analytical work. This 'standard deviation of duplicates' (SD 
dups) computer program, written by Dr P. Raggatt (Dept Clinical Biochemistry, 
Addenbrooke's Hospital, Cambridge) requires analyte concentrations to be assigned to 
one of seven 'bins', which should span the assay working range. The individual Lp(a) 
concentrations from each pair of replicates is entered into the program which then 
calculates the mean of each duplicate, the SD and percentage difference of the 
replicates. For reliable analysis at least fifty values should be present in each of the 
bins. Once sufficient data is entered, the program calculates the mean of the 
duplicates in each bin. The mean SD of the duplicates of each result and the CV is 
calculated from these results. A plot of bin mean Lp(a) concentration against CV 
gives an estimate of assay precision across the analyte range. An assay with 
coefficients of variation below 8% across the assay range may be regarded as precise 
(237),
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6.2.1 Results.
Within-batch precision.
Table 6.1 shows within-batch precision data for various combinations of 
capture and detection antibodies at three analyte concentrations.
Table 6.1
Antibody combination n mean [Lp(a)] 
(mg/L)
SD
(mg/L)
CV
(%)
(a)-(a) 12 71 3.5 5.0
12 717 15.5 2.2
(a)-B 10 41 1.2 2.8
10 354 18.1 5.1
10 527 38.6 7.3
29clO-B 10 96 5.8 6.0
10 311 11.2 3.6
10 559 12.9 2.3
35f5-B 10 108 2.8 2.6
10 304 13.9 4.6
10 441 17.6 4.0
35f5-(a) 12 40 1.9 4.7
12 397 10.3 2.6
12 825 33.0 4.0
35f5-29cl0 11 25 1.8 7.2
11 398 5.4 1.4
11 855 3.9 4.6
Abbreviations for the antibodies used :
(a) = 'Immuno' polyclonal anti-apo (a) antibody;
B ='Binding Site' polyclonal anti-apo B antibody;
29cl0 or 35f5 in-house monoclonal anti-apo (a) antibodies.
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Between-batch precision.
For reliable between-batch precision studies, it is accepted practice that data from at 
least 20 separate assays is required.
The only antibody combination in which 20 Lp(a) assays were run was 29clO-B.
Data obtained at 4 analyte concentrations from the 20 assays is shown in table 6.2
Table 6.2
Between batch precision data for the 29clO-B time-resolved fluorescence Lp(a) assay 
at 4 analyte concentrations.
Mean (mg/L) SD (mg/L) CV (%)
39.5 3.4 8.6
157 10.8 6.9
407 26.6 6.5
940 70.5 7.5
Limited data (from 8 assays) suggested a similar between-batch precision could be 
achieved using the (a)-B assay (data not shown).
Precision profile.
This was assessed only for the 29clO-B assay. At least 25 data points were 
present in each bin. In total 203 pairs of results were used in the calculations, 172 
(85%) of them had less than 10% difference between the replicates (which is very 
good for an immunoassay), a further 16 (8%) had differences between 10 and 15 % 
and the remaining 13 (7%) had differences greater than 15%.
A plot of bin mean against %CV is shown in figure 6.1.
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6.2.2 Discussion.
The precision data obtained in the time-resolved fluorescence assay for each 
antibody combination is well within limits deemed to be acceptable for an 
immunoassay (237) The data compares favourably with that produced by 
manufacturers of commercial ELISA assays who quote between-batch CV in the 
region of 5-10 % and within-batch CV in the order of 3-8 % (214-218) practice, the 
Immunozym® ELISA assay used in this department has a between-batch variation in 
excess of 10% for quality control materials with Lp(a) concentrations of 250 and 350 
mg/L. Improvements in assay precision may be made in two ways. Firstly, use of a 
robotic sample pipetting station such as the Tecan RSP 3032 would almost certainly 
improve precision of duplicates when compared to manual pipetting techniques. 
Secondly, the preparation of standard materials may be improved; the current practice 
of diluting and double diluting an aliquot of standard for each assay is prone to errors 
and between-batch variation. Improvements may be made by diluting the stock 
standard material to produce a series of standards which are then frozen in aliquots. 
These aliquots would then be diluted in assay buffer (i.e. 1:1000 for the 29clO-B 
assay).
6.3 SENSITIVITY.
6.3.1 Method.
The sensitivity of an immunoassay^ may be defined as the lowest analyte 
concentration that may reliably be distinguished from zero. This is usually estimated 
by analysing at least twenty replicates of the zero standard (assay buffer), together 
with a standard curve, in one assay. The mean and standard deviation of the zero 
counts are calculated and the analytical sensitivity is determined as the analyte 
concentration at which the (mean + 3 x SD) counts intercept the standard curve (^^0.
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6.3.2 Results.
Mean (+ SD) of fluorescence counts from 20 replicates of the zero standard 
are presented in table 6.3, together with counts for the lowest standard the assay. This 
data was used to assess sensitivity as described in 6.3.1, in cases where the (mean + 3 
SD) counts were less than the lower standard, the response between zero and that 
standard was assumed to be linear.
Table 6.3
Mean (+ SD) of fluorescence counts from 20 replicates of the zero standard in the 
29clO-B time-resolved fluorescence Lp(a) assay. The data was used to estimate assay 
sensitivity.
Antibody
Combination
Zero std counts 
Mean SD
Std counts 
(3 mg/L)
Sensitivity
(mg/L)
35f5-(a) 1463 104 2425 1
35f5-29cl0 1087 72 1602 2
29clO-B 865 62 1451 1
Data from the 35f5/B and (a)/B assay (not shown) also produced assay sensitivities of 
2 mg/L.
A sensitivity of 1 mg/L in an assay using 200pl of a 1:1000 sample dilution means 
that, in absolute terms, lp,g/L of lipoprotein (a) is detected.
The sensitivities achieved for the time-resolved fluorescence Lp(a) assays are 
superior to those quoted for commercial kits. ELISA kit manufacturers claim 
sensitivities o f  between 10 and 20 mg/L (214,216) Information from Immuno suggests 
that their immunoturbidimetric assay has a sensitivity of 50 mg/L and the Pharmacia 
IRMA assay has a sensitivity of around 3 mg/L (^ ^^ ).
To some extent assay sensitivity is dependant upon the antibody combination 
employed. For instance, if the detection antibody was directed against the kringle 4
120
repeating domains of Lp(a) then, even at low analyte concentrations, it may be 
possible to bind several labelled antibodies, thus giving a relatively large 
fluorescence signal. Conversely, if an anti-apo B detection antibody was used, it may 
only be possible to bind only one detection antibody, therefore giving a lower 
fluorescence signal and lower sensitivity.
The 1:1000 sample dilution employed in the 29clO-B assay means that if 
greater sensitivity is required, a lower sample dilution may be used, (e.g. 1:100) 
which should improve the apparent sensitivity to 0.2 mg/L. Whether this degree of 
sensitivity would ever be necessary when measuring Lp(a) in a human serum sample 
is debatable. However, it may be useful (as a research tool) in detecting the presence 
of Lp(a) in other body fluids or cell culture supernatants.
6.4 LINEARITY ON DILUTION.
6.4.1 Method.
Measured [analyte] in samples analysed by immunoassay should decrease in 
proportion to sample dilution. However, at lower analyte concentrations other factors 
(such as assay imprecision) may produce non-linear dilution. Failure of samples to 
dilute in a linear fashion may also be due interfering factor(s) which only influence 
the assay at high concentration (i.e. the interfering factor may be 'diluted out'). To 
assess linearity, a series of at least two dilutions were made on a series of samples 
with elevated Lp(a) concentrations. The undiluted sample plus 1:2 & 1:4 dilutions (in 
phosphate-buffered saline, pH 7.4) were then analysed in duplicate in one batch and 
the measured Lp(a) concentration was plotted against dilution factor.
6.4.2 Results.
Figure 6,2 shows a series of samples (with high and low Lp(a) concentrations) 
that were diluted and assayed using the 29clO-B antibody combination. The dilution 
factor refers to the proportion of the undiluted sample remaining (where the undiluted
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sample has a dilution factor of 1.0). Samples diluted in assay buffer to the standard 
assay dilution of 1:1000 were then diluted further and assayed.
Dilution data presented graphically reveals linearity if the line of best fit 
between the points passes through the origin and the correlation coefficient of the fit 
between the points on the line (r) is greater than 0.9. It is apparent from figure 6.2 
that these criteria are achieved for these samples.
Similar dilution patterns were observed for most of the other antibody 
combinations (data not shown). However, dilutions in the (a)-(a) assay deviated 
somewhat from linearity, possibly because the same antibody was used to both 
capture and to detect the Lp(a). In practice, because of the wide working range of the 
time-resolved fluorescence assays, pre-dilution of patient samples should not be 
necessary. Other commercial assays with upper limits of measurement at around 700- 
800 mg/L require that some samples be pre-diluted.
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6.5 COMPARISON WITH OTHER Lp(a) ASSAYS.
These comparisons may either be performed directly (i.e. analysis of a group 
of samples in each assay) or by comparison of data obtained from external quality 
control schemes.
6.5.1 External quality control schemes.
During this project two external quality control schemes for Lp(a) were 
operating in this country (organised from Manchester and Bristol). Aliquots of 3-6 
different serum samples were sent to each laboratory participating in the scheme at 
two-monthly intervals. The samples were analysed and the results were returned to 
the scheme co-ordinator together with details of the analytical method employed. 
Results are compared with those obtained by other participants using the same or 
differing methodologies. The aim of these schemes is to produce consistency of 
results amongst its users. For external quality control data to be valid, it is important 
that there is a sufficient number of participants in the scheme (ideally, at least fifty) to 
produce accurate mean values. For the Lp(a) schemes presented here, the maximum 
number of participants at any one time was fifteen, who used five different analytical 
methods,
53 samples from the Manchester scheme were analysed retrospectively after 
storage for up to two years at -70°C. Samples from the Bristol scheme were divided 
into aliquots and frozen at -20®C on receipt and analysed within seven days. All 
samples were thawed, mixed thoroughly and centrifuged before analysis using the 
29clO-B assay. Pooled internal quality control sera were analysed together with these 
samples. The measured Lp(a) concentrations for these samples were within acceptable 
analytical ranges.
Results.
The Lp(a) results obtained using the time-resolved fluorescence assay were 
plotted against the mean result (for that sample) from other laboratories using each
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kit. These plots are not presented but correlation data from the 'line of best fit' 
through the data points is shown in table 6.4.
The correlation refers to the equation y = mx + c (238) where:- 
y = Time-resolved fluorescence assay result, 
m = Slope of the correlation line ; x = commercial assay result, 
c = intercept of the correlation line, 
also : n = number of results in the correlation 
r = Correlation coefficient.
Table 6.4
Correlation data obtained from comparisons of Lp(a) results generated using an in- 
house time-resolved fluoroimmunoassay and 5 different commercially available
ASSAY n X c r
Biopool ELISA 50 0.76 -0.4 0.835
Innotest ELISA 25 1.00 -1.3 0.827
Immuno ELISA 50 0.966 -1.4 0.850
Pharmacia IRMA 50 1.22 2.5 0.878
Turbidimetry 50 0.88 6.0 0.876
This data demonstrates that, in general, there is a reasonably good correlation between 
the results produced by different assays (r >0.8). However, the slopes of the 
correlation lines (0.76-1.22) indicate that there is a difference in the measured Lp(a) 
concentrations. It was also apparent from the correlation plots (data not shown) that 
up to 2-fold variations in serum Lp(a) concentrations may occur when samples are 
analysed using different analytical methods.
A comparison of Lp(a) results for each sample obtained using the time- 
resolved fluorescence assay with the overall mean of results for the same sample 
measured using the other assays is shown in figure 6.3. The data indicates that a 
good correlation was obtained; the slope of the correlation line suggests that the time-
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resolved fluorescence assay gives results ~10% higher than the mean result from other 
methods. The time-resolved fluorescence assay results were also expressed in terms 
of standard deviations from the mean result of all methods (figure 6.4). This plot 
showed 50/53 results fell within +/- 2 x SD of the overall mean result for each sample. 
The +/- 2SD of the mean is widely accepted as representing acceptable analytical 
performance in an external quality control scheme (239) However, in this scheme, 
(because of the small number of participants and wide analytical variation) the 
standard deviation for results obtained for each sample was quite large.
It was apparent that analysis of the external quality control samples would 
yield little useful information on the performance of the time-resolved fluorescence 
assay for the following reasons :
(i) The most results returned for any one sample was 15 and for some samples 
there were only 6 results. A reliable estimate of mean and SD ideally requires at least 
20 data points.
(ii) Five different assays were employed, each using different antibody 
combinations and standards which is likely to exaggerate any between-laboratory 
variability.
The only conclusions that can reliably be drawn from this study is that the 
time-resolved fluorescence assay is not drastically out of consensus with the others. 
However, since samples with Lp(a) concentrations above 500 mg/L have not been 
distributed in this scheme, it is possible that limitations of the analytical performance 
of commercial assays may be even more evident at this high concentration.
The Bristol QC scheme, as yet, has only 6 participants. This makes 
interpretation of results even less reliable than for the Manchester scheme. The 
results returned so far (9 samples) have again shown wide inter-laboratory variations 
(e.g. 360-890 mg/L on one sample). The time-resolved fluorescence assay gives 
results slightly greater than the overall mean.
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6.5.2 Comparisons with a commercial kit assay.
The Immunozym® ELISA assay was used to measure Lp(a) in some research 
projects undertaken by this department. Human serum samples analysed using this kit 
were also analysed using the 29clO-B time-resolved fluorescence assay. Quality 
control samples were analysed in both assays and the values obtained were within 
acceptable analytical ranges.
Figure 6.5 compares results obtained in the two assays using the same 
standard. Although the number of data points is small, it is apparent that the time 
-resolved fluorescence assay generates results up to 50% higher than the Immnozym® 
assay. The reason for the differences in results is probably due to the antibody 
combinations used in the assays, the Immunozym® assay uses two anti-apo (a) 
antibodies while the 29clO-B assay uses one anti-apo (a) and one anti-apo B antibody. 
A publication from Immuno compared their commercial (a)-(a) ELISA assay 
with an ELISA (of similar design) using an anti-apo (a) detection antibody in place of 
the anti-apo B detection antibody. The results they obtained for this (a)-B assay were 
-40% higher than for the (a)-(a) assay, this agrees well with comparison data from the 
29clO-B assay and the Inununozym® ELISA.
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6.6 COMPARISONS BETWEEN DIFFERENT TN-HOUSE’ TIME-RESOLVED 
FLUORESCENCE ASSAYS.
6.6.1 Method.
A series of 24 human serum samples were analysed using microtitre plates 
coated with one of the three different anti-apo . (a) capture antibodies ('Immuno' anti- 
apo (a), and the 35f5 & 29c 10 monoclonal antibodies) together with the europium 
labelled anti-apo B detection antibody. The assays were performed on the same day 
using the same standards. Quality control materials, assayed in each batch, were 
within acceptable analytical limits.
6.6.2 Results.
The results for the samples obtained using each antibody combination are 
presented in table 6.7 It may be seen that 21/24 samples showed good agreement. 
However, the other three (samples 1, 4 & 9) gave discrepant results. As the same 
detection antibody was used in each case, this strongly suggests that the capture 
antibodies have different affinities for the isoforms of Lp(a) in these samples.
A larger study was performed in which results from two Lp(a) assays using a 
monoclonal anti-apo (a) capture antibody and a polyclonal anti-apo B detection 
antibody (35f5-B & 29clO-B) were compared. These comparisons are presented in 
figure 6.6. This plot demonstrates that for a large number of samples the correlation 
between the two assays is excellent.
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Table 6.5.
A comparison of Lp(a) results (in mg/L) for 24 serum samples measured using three 
different time-resolved fluorescence assays.
Sample number (a)-B 35f5-B 29clO-B
1 75 120 210
2 470 390 450
3 550 440 550
4 260 420 650
5 910 950 1190
6 13 12 16
7 62 55 68
8 360 270 280
9 320 460 920
10 62 53 67
11 320 280 340
12 120 130 180
13 92 100 130
14 35 36 44
15 54 54 50
16 140 180 240
17 560 610 650
18 160 290 330
19 440 460 440
20 480 560 600
21 280 330 300
22 190 210 220
23 70 85 80
24 17 19 20
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6.7 INTERFERENCE.
6.7.1 Methods.
Assay interference resulting from biomolecules present in body fluids has long 
been recognised. Interferences may be due to pigments that affect colourimetric 
measurements or, more specifically, cross-reactivity between molecules. The 
measurement of Lp(a) presents a particular interference problem in that the structure 
of Lp(a) is homologous to other serum proteins such as apolipoprotein B (which is 
present in large quantities in lipoproteins such as LDL) and plasminogen (which has a 
structure similar to apolipoprotein (a)).
To investigate the possibility of interference in Lp(a) assays serum samples 
with known Lp(a) concentrations were 'spiked' with test compounds obtained 
commercially. The test agent was added to a final concentration in excess of the 
highest concentration found in human serum.
6.7.2 Results.
Plasminogen interference.
The effect of plasminogen on three Lp(a) assays was investigated. In theory, because 
of the structural similarities between apo (a) and plasminogen, the assays most likely 
to be affected by plasminogen are those using two anti-apolipoprotein (a) antibodies.
29cl0 - B assay : Plasminogen was added to two serum samples, with high or low 
concentrations of Lp(a), to a final concentration of 99, 186 and 372 mg/L (in addition 
to the endogenous plasminogen concentration). Samples were then analysed in 
triplicate. A plot of plasminogen added versus measured Lp(a) concentration (figure 
6.7) shows that addition of plasminogen at concentrations above those seen in normal 
human serum (^ 40) has no effect on measured Lp(a) concentrations.
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(a)-(a), 35f5-{a) & 35f5-29cl0 assays : Plasminogen was added to a serum sample 
with a low concentration of Lp(a) to final concentrations of 70,140 and 279 mg/L (in 
addition to the endogenous plasminogen concentration). Samples were then analysed 
in duplicate. A plot of plasminogen added versus measured Lp(a) concentration 
(figure 6.8) again shows that addition of plasminogen at concentrations above those 
seen in normal human serum (240) has no effect on measured Lp(a) concentrations.
None of the antibody combinations that were tested are affected by high 
concentrations of plasminogen. The reasons for this may be different in each case.
In two-site assays employing an anti-apo B detection antibody, binding of 
plasminogen to the detection antibody should not occur. Therefore the only possible 
mode of interference would be competition between plasminogen and Lp(a) for 
binding sites on the anti-apo (a) antibody coated plates. Since these binding sites 
(even if they bound plasminogen) are present in great excess, it was unlikely that 
interference could occur.
Assays using two anti-apo (a) antibodies were most likely to be susceptible to 
plasminogen interference. There is evidence (chapter 5) that the in-house monoclonal 
antibodies are directed against the kringle 4 domains of apo (a). These domains are 
present in plasminogen, hut the antibodies do not appear to cross-react.
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Bilirubin interference.
Bilirubin was investigated as a possible interfèrent since it was known to 
quench fluorescence under certain conditions (241). Bilirubin was added to serum 
samples over the range 120-900 p,mol/L. The final bilirubin concentrations in each 
sample (estimated on the DuPont Dimension AR® autoanalyser) were 6, 124, 248, 
531,720 and 908 jimol/1. The samples were then assayed for Lp(a), in triplicate, using 
the 29clO-B assay. A plot of bilirubin concentration versus measured Lp(a) 
concentration (figure 6.9) indicates that at concentrations up to 50 times those found 
in human serum (242) bilirubin had no effect on measured Lp(a) concentrations.
Other possible interferents have not been investigated. Although it is likely 
that the specificity of a two-antibody procedure coupled with a large sample dilution 
would prevent interference from other biomolecules, this possibility has not yet been 
investigated. LDL and other apo B-containing proteins may be a problem in a one- 
step (a)-B assay due to competition for the detection antibody. In the two-step assay 
format used in this project the possibility of interference from these proteins is 
unlikely because apo B should not bind to the anti-apo (a) capture antibody.
CONCLUSIONS.
The data shows that the time-resolved fluorescence assay is superior in terms 
of sensitivity, precision and working range to any of the commercial assays. 
Comparisons of results for serum samples with those obtained from the commercial 
kits showed considerable variability which is probably due to the different antibody 
combinations and standards used in the assays. The only method by which 
comparability of measured Lp(a) results may be achieved is by the use of the same 
combination of antibodies and the same standard material containing a mixture of 
Lp(a) isoforms, although this is not likely to happen in the foreseeable future.
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CHAPTER?
CLINICAL MEASUREMENTS USING THE DELFIA® Lp(a) ASSAY
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7.1 ESTABLISHMENT OF A 'REFERENCE RANGE' (243) for SERUM Lp(a).
7.1.1 Method.
200 serum samples (98 from females, 102 from males) were analysed for 
Lp(a) using the 29clO-B assay. The samples were obtained from healthy Caucasian 
blood donors. Serum was frozen at -20°C on the day of venepuncture and stored for 
three months at the same temperature before analysis. The age of the subjects ranged 
from 17 to 67 years.
7.1.2 Results.
Population distribution of serum Lp(a) concentrations.
Figure 7.1 shows the distribution of serum Lp(a) concentrations for the 200 
adults. Lp(a) was detectable in all of the samples assayed: the lowest concentration 
was 4 mg/L and the highest was 1380 mg/L. Lp(a) was also measured in a further 
one hundred hospital in-patient serum samples each of which had concentrations of 
Lp(a) well above the detection limit (1 mg/L) of the assay (data not shown). This 
strongly suggests that Lp(a) is normally present in the serum of healthy Caucasian 
adults.
Comparison of serum Lp(a) concentrations in males and females.
Figure 7.2 shows a comparison of the distribution of serum Lp(a) 
concentrations in males with those in females: the male group had a mean 
concentration of 210 mg/L (median of 120 mg/L) while the female group had a mean 
of 236 mg/L (median of 110 mg/L). This data suggests that there is no significant 
difference in serum Lp(a) concentrations between healthy adult Caucasian males and 
females. The findings are consistent with previous studies in which sex-independent, 
highly skewed distributions of serum Lp(a) concentrations were reported for the 
Caucasian population (43).
139
oo oco o(O o
CM o
co O)
0
O)
E
cg
(5
(D
ü
c
8
SÛ.
(A
CO CA
0)ü
C
o
o
3 
(A
Cg
(A
«• s
i =
M -  3 K
o  g
C JJJ 
O (D -C
Is
Q .5
0)
3
O
sioefqns ;o jeqiunisj
140
' - i'
0)0) n)1 I
co
CD
(0
E
aII
5  (O ^  0) c  -=<D (0ü  Eco  ^  ü  3
«■ ® | l
O O 
c/) O  
C\J
°  o
5  2  
5  o>
% «
Q  .5
spafqns p  jaqiunN
oi
M
0)k.
3
O
141
Many clinically useful analytes (e.g. serum potassium) show a Gaussian (bell­
shaped) distribution in the healthy population. It is accepted procedure (^ 3^) that, for 
this type of distribution, subjects with analyte concentrations between +/- 2 standard 
deviations of the mean concentration are deemed 'normal'. Statistically, this figure 
represents 95% of a normally distributed population, i.e. 1 in 20 of the healthy 
population have analyte concentrations outside this normal' range. This statistical 
analysis does not apply to skewed analyte distributions (as presented here for Lp(a)). 
However, logarithmic transformation of data from skewed distributions may produce 
a Gaussian type curve (243). Unfortunately, however, logarithmic transformation of 
the highly skewed Lp(a) data does not generate such a curve.
Other strategies for establishment of a Lp(a) reference range were therefore 
investigated. The percentage of the population with Lp(a) concentrations below 
certain values was determined:- 3.5% had a serum Lp(a) concentration below 10 
mg/L, 46% had a concentration below 100 mg/L, 73% had a concentration below 300 
mg/L, 87% had a concentration below 500 mg/L and 95% of the population had 
serum Lp(a) concentrations below 780 mg/L. From this data it is obvious that 95% 
confidence limits cannot be used to establish a 'reference range', mainly because only 
patients with the most elevated of Lp(a) concentrations would be classified as 
abnormal. Current views (*0) are that Lp(a) concentrations above 300 mg/L are 
associated with an increased risk of coronary artery and other vascular diseases. This 
limit was determined by retrospective clinical assessment of patients with coronary 
heart disease whose Lp(a) was measured using assays employing two anti-apo (a) 
antibodies. In this project (see chapter 6) and other studies (215) assays using one anti- 
apo (a) and one anti-apo B antibody gives results that are -40% higher than those 
using two anti-apo (a) antibodies. Hence, it may be that a discriminatory value of 420 
mg/L should apply when assays using this antibody combination are employed.
Data presented in chapter 6 has examples of serum samples which produced a 
wide range of results in assays employing several different antibody combinations. 
For example, one sample gave results varying from 360-890 mg/L. Such wide
142
analytical variability makes clinical interpretation of Lp(a) results very difficult. It 
may be that only patients with Lp(a) concentrations below 200 mg/L, and with no 
other associated coronary risk factors, may be classified as having a low risk of 
coronary artery disease.
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7.2 AGE-DEPENDENT VARIATIONS IN SERUM Lp(a) CONCENTRATION.
Serum from 200 healthy Caucasian adults, 62 children and 21 samples of cord 
blood were analysed using the 29clO-B assay. The paediatric samples were obtained 
from hospital in-patients with an age range from one week to 15 years. The cord 
blood was collected following uncomplicated delivery.
7.2.1 Results.
Adults : The distribution of serum Lp(a) concentrations with age in the 200 
healthy Caucasian adults is shown in figure 7.3. It is apparent that there is no 
correlation between age and serum Lp(a) concentration.
Cord blood : The distribution of Lp(a) concentrations is presented in figure
7.4. Twenty samples had serum Lp(a) concentrations below 40 mg/L whereas a 
single sample had a concentration of 110 mg/L. All samples were found to have 
measurable concentrations of Lp(a), the lowest of which was 1 mg/L.
Children : The distribution of serum Lp(a) concentrations is shown in figure
7.5. The shape of the distribution pattern was similar to that obtained for adults (fig 
7.3), although the Lp(a) concentrations were lower. As with adults there was no 
obvious correlation between age and Lp(a) concentration (data not shown). However, 
this group of children could not be regarded as 'normal' because many of the subjects 
were hospitalised due to a metabolic disorder or were receiving parenteral nutrition.
These findings are consistent with previously published data. No correlation 
has ever been made between serum Lp(a) concentrations and age in healthy 
Caucasian adults (33). The finding of low Lp(a) concentrations during the neonatal 
period has also been documented (^ )^. Various studies (43-45) have suggested that adult 
levels of Lp(a) are attained by late childhood and thereafter remain constant. 
However, in the absence of a long term research investigation into healthy juvenile 
serum Lp(a) concentrations, this is difficult to confirm.
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7.3. TIME-DEPENDANT VARIATION IN SERUM Lp(a) CONCENTRATIONS.
7.3.1 Method.
Blood samples were collected from two healthy female volunteers (aged 
between 20-30 years) on five consecutive days. The subjects were fasted overnight 
and blood was collected at 9 a.m. the following day. The blood was centrifuged and 
the serum was separated and frozen at -20°C. All 5 samples were stored for 2 weeks 
then thawed, centrifuged and analysed (in duplicate) using the same 29clO-B assay. 
Quality control samples assayed with the batch fell within acceptable analytical 
limits.
7.3.2 Results.
The serum Lp(a) concentrations for each of the subjects are shown in figure
7.6. Both subjects had low serum Lp(a) concentrations. However, since the assay is 
very precise at these concentrations (coefficient of variation of 6% at a concentration 
of 40 mg/L) it is unlikely that the large percentage variations in Lp(a) concentration 
seen for subject 1 was due to assay imprecision.
The possibility that venous stasis during blood collection may have 
artefactually elevated the serum concentrations of large molecules (such as proteins) 
was investigated. Serum total protein and albumin concentrations (which normally 
change little from day-to-day in healthy individuals but rise following prolonged 
venous stasis) were measured using the DuPont Dimension® autoanalyser. 
Concentrations for subject 1 are presented in table 7.1. Protein concentration 
variations greater than 10 g/L would indicate significant haemoconcentration.
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Table 7.1
Lp(a)
mg/L
T.Protein
g/L
Albumin
g/L
Day 1 23 74 43
Day 2 33 74 43
Day 3 42 69 41
Day 4 43 68 40
Day 5 28 70 41
This data suggests that haemoconcentration was not the cause of the 
variability of Lp(a) concentration. Unfortunately no further volunteers were 
recruited, but further studies into this large percentage variation (particularly if it is 
repeated at high concentrations of Lp(a)) might prove to be very important to the 
interpretation of Lp(a) measurements.
7.4. DISCUSSION.
Data from the short clinical studies presented in this chapter is in close 
agreement with previously published findings. These findings confirm that the time- 
resolved assay performs in a similar manner to the commercially available kit assays 
used in other studies.
Many studies have been performed in recent years in which serum Lp(a) 
concentrations have been measured in various disease states, and following drug 
therapy. A collaborative study with consultant cardiologist. Dr P. Weissberg, at 
Addenbrooke's Hospital has recently begun. The aim of the study is to screen 
patients attending the hospital lipid clinic to identify those with raised serum Lp(a) 
concentrations and to assess the effectiveness of a drug therapy aimed at lowering 
serum Lp(a) concentrations in volunteers from this group. The project is, at yet, only 
at the screening stage.
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CHAPTERS
EFFECT OF DETERGENTS ON SERUM Lp(a) MEASUREMENTS
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8.1 INTRODUCTION,
It has been suggested that Lp(a) has a tendency to self-associate (i.e. 
aggregate), particularly following freeze-drying procedures (21%). If such self­
association also occurs in vivo, it is possible that Lp(a) concentrations measured by 
immunoassay might not reflect the true serum Lp(a) concentration.
Detergents are commonly used to dissociate large insoluble lipid aggregates 
into smaller, more soluble, micelles. The effect of adding different detergents to the 
buffers used in the time-resolved fluorescence assay for Lp(a) was therefore 
investigated.
Three different types of detergent are available (244)
(i) Ionic Detergents are molecules consisting of a hydrocarbon chain and a strongly 
acidic or basic polar group. An example of this class of detergent is sodium dodecyl 
sulphate (SDS). Ionic detergents frequently cause dénaturation of proteins in 
solution.
(ii) Non-Ionic Detergents are molecules consisting of a hydrocarbon chain with a 
polyoxyethylene polar region. They rarely cause structural damage to proteins and 
consequently are frequently incorporated into assay buffers. These detergents are 
particularly useful in immunoassays, where the addition of small amounts of 
detergent to the reaction mixture may significantly reduce non-specific binding of 
labelled antibodies.
A wide range of non-ionic detergents are commercially available with 
molecular weights ranging from 500-2000 Daltons. Examples include the Triton' 
(Alkylphenyl Polyoxyethylene ether) and 'Tween' (Acyl polyoxyethylene ether) 
series.
(iii) Bile salts (anionic detergents) consist of a steroid ring structure with hydroxyl 
groups located on the outside of the molecule and an ionic group at one end. This 
structure is completely different to the other two types of detergent and, consequently, 
the physical structure of micelle formation is different to those formed with ionic and 
non-ionic detergents. Examples of bile salts are cholic acid and deoxycholic acid.
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The assay buffer (Tris HCl) provided with commercial DELFIA® kits contains 
the detergent Tween 20 at a concentration of 0.02% (v/v). When serum samples were 
analysed following dilution in this buffer, or in Tween 20-free Tris-HCl buffer, there 
was no difference in the fluorescence signals obtained (data not shown). This suggests 
that the low concentration of detergent had little effect on the Lp(a) assay. DELFIA® 
assay buffer was therefore used for dilution of serum samples in this study, with 
addition of other detergents as required.
8.2 Effect of non-ionic detergents.
Serum Lp(a) was assayed in microtitre plates coated with either the Inununo" 
polyclonal anti-apo (a) antibody or the monoclonal antibody, 35f5, in conjunction 
with a europium-labelled anti-apo B detection antibody. Serum samples were diluted 
1:1000 in assay buffer containing the non-ionic detergent, Triton X-100, at 
concentrations up to 10% (v/v). Fresh Triton/buffer solutions were prepared for each 
assay.
8.2.1 Results.
In the first experiment, a series of randomly selected serum samples were 
analysed (together with the Lp(a) standard) following dilution in assay buffers 
containing Triton X-100 at 0-10% (v/v) using an anti-apo (a) coated plate. The 
standard Lp(a) assay protocol was used (chapter 5, appendix 5.1).
Figure 8.1 shows the dose-response curves for the Lp(a) standard diluted in 
buffers containing Triton X-100 at 0, 2 and 4% (v/v). Figure 8.2 shows the 
percentage increase in fluorescence signal (which is proportional to measured Lp(a) 
concentration) for 8 serum samples assayed after dilution in buffers containing Triton 
X-100 at 0-10% (v/v). The percentage increase in signal was calculated by comparing 
the fluorescence counts obtained when the sample was diluted in Triton-free buffer to 
those obtained when the sample was diluted in detergent-containing buffers.
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These data demonstrate that significant increases in fluorescence signal may 
be obtained when Triton X-100 is added to the assay buffer. Increases were greater 
than 100% for some of the serum samples. The percentage signal increase does not 
appear to be related to the Lp(a) concentration of the samples.
A similar experiment was performed with the same samples using a 35f5 
coated plate (results shown in figure 8.3). The percentage increases in signal were less 
than those obtained using anti-apo (a) coated plates; indeed, two of the eight samples 
showed a slight decrease in fluorescence signal when Triton X-100 was added to the 
assay buffer. Assays employing anti-apo (a) antibodies to both capture and detect 
Lp(a) also showed an increase in fluorescence signal when Triton was added to the 
assay buffer (data not shown).
8.2.2 Discussion.
The variable fluorescence signal increases observed with different capture 
antibodies may be related to their binding to different epitopes on Lp(a). The 
increases in signal may be explained as follows: if the 'Immuno' polyclonal anti-apo 
(a) antibody recognised additional epitopes that are usually buried within aggregated 
Lp(a) particles, then breakdown of the aggregate would cause a marked increase in 
available antibody binding sites. This would lead to more Lp(a) binding to the plate, 
which in turn would lead to an increased fluorescence signal. Conversely, if the 35f5 
antibody recognised an epitope that is solely on the surface of aggregated Lp(a), then 
breakdown of the aggregate is less likely to release fewer additional binding sites and, 
therefore, cause a smaller increase in fluorescence signal. A high proportion of the 
total increase in fluorescence signal was achieved by increasing the Triton X-100 
concentration in the assay buffer from 0 to 1% (v/v). Further addition of Triton 
produced only a small additional increase in signal.
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8.3 Effect of sample storage.
The possibility that freezing of serum samples causes aggregation of Lp(a) 
was investigated, A series of 4 serum samples were selected, and a portion of each 
sample was divided into aliquots and frozen at -20°C, whilst the remainder was stored 
at 4 ®C, Samples were stored at each temperature for 1 day after venepuncture.
One aliquot of each frozen sample was thawed (in air) at 20°C whilst another 
was thawed in a waterbath at 37°C . Each of these aliquots, along with aliquots of 
serum stored at 4®C (and subsequently brought to room temperature), were mixed and 
centrifuged at 20°C. The samples were analysed in assays using the (a)-B or 35f5-B 
antibody combination after dilution in assay buffer containing 0,1 or 4 % (v/v) Triton 
X-100. Standard curves were generated for each of the possible antibody 
combinations and Triton X-100 concentrations. Results are presented in table 8.1.
It is apparent from the data that:
(i) All samples displayed some increase in their measured Lp(a) concentrations 
when Triton was added to the assay buffer.
(ii) The increase in Lp(a) concentration was greater using the anti-apo (a) coated 
plates.
(iii) The method of sample storage or thawing had little effect on the measured 
Lp(a) concentration. This suggests that freezing of serum does not enhance 
aggregation of Lp(a).
(iv) The percentage increase in measured Lp(a) concentration appeared to be 
independent of Lp(a) concentration (over the range -40-390 mg/L).
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Table 8.1 ; Lp(a) concentrations of 4 serum samples (stored and thawed in three 
different ways) measured using the (a)-B and 35f5-B assay with buffers containing 
0,1 & 4 % (v/v) Triton X-100.
(a)-B assay.
Stored at -20®C 
Thawed at 20®C Thawed at 37°C
Stored at +4°C
Sample 0% 1% 4% 0% 1% 4% 0% 1% 4%
1 190 290 340 160 280 330 150 290 330
2 390 880 920 380 850 950 370 750 830
3 40 60 70 50 70 70 40 60 70
4 250 540 610 280 560 600 250 530 600
35f5 -B assay.
Stored at -20°C 
Thawed at 20°C Thawed at 37°C
Stored at +4°C
Sample 0% 1% 4% 0% 1% 4% 0% 1% 4%
1 270 270 300 220 280 300 220 280 290
2 660 820 1040 640 810 980 620 820 950
3 50 60 70 70 70 80 50 60 70
4 520 610 670 480 620 680 500 620 680
157
The observed increase in measured Lp(a) concentration when serum samples 
and standards were assayed in buffers containing Triton X-100 suggests that the 
serum samples gave a greater increase in signal than the Lp(a) standard. If both 
signals had increased proportionately then the measured Lp(a) concentration in the 
serum samples would have remained the same.
Samples analysed using microtitre plates coated with the two different capture 
antibodies produced widely different results. For instance, sample 4 had 
concentrations ranging between 250-280 mg/L when analysed using the anti-apo (a) 
coated microtitre plates and 480-520 mg/L when plates coated with 35f5 were used. 
However, addition of 4% (v/v) Triton to the assay buffer, increased measured Lp(a) 
concentration to 600-610 mg/L and 670-680 mg/L respectively. These findings are 
consistent with the hypothesis that aggregation of Lp(a) prevents its binding to anti- 
apo (a) coated plates to a greater extent than to the 35f5 coated plates. It is therefore 
possible that assays using microtitre plates coated with the 35f5 monoclonal antibody 
(with or without Triton in the assay buffer) give a better estimation of true serum 
Lp(a) concentrations.
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8.4 Are fluorescent signal increases due to addition of Triton to the assay buffer 
time-dependant ?
In previous experiments the increase in fluorescence signal were obtained 
when samples (diluted in assay buffer containing Triton X-100) were incubated with 
the capture antibody for a fixed period of three hours. An experiment was performed 
to determine whether pre-incubation of the sample with Triton-containing assay 
buffer would release more Lp(a) from the aggregates.
Four samples were diluted in assay buffer containing 0,1 and 4 % (v/v) Triton 
X-100 and incubated overnight at 4®C. The following day these diluted samples were 
analysed, together with the same four samples that had been freshly diluted in buffer 
containing the same concentrations of detergent. A series of Lp(a) standards were 
also assayed following dilution in buffer containing each of the three Triton 
concentrations. The assay was performed using an anti-apo (a) coated microtitre plate 
with an anti-apo B detection antibody. Results are presented in table 8.2.
Table 8.2 : Serum Lp(a) concentrations for 4 samples measured in the (a)-B assay 
using buffers containing 0, 1 or 4 % (v/v) Triton X-100. One set of samples was 
diluted and pre-incubated overnight at 4®C in these buffers, the other was freshly 
diluted.
Lp(a) concentrations (mg/L)
Sample 0% Triton 1% Triton 4% Triton 0% Triton 1% Triton 4% Triton
1 210 310 330 220 300 350
2 390 860 940 380 870 900
3 40 70 80 60 70 70
4 250 530 600 250 550 610
It is evident from this data that increasing the incubation time has no effect on 
measured Lp(a) concentration. This suggests that the dissociation of aggregated 
Lp(a) particles by detergents occurs rapidly.
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8.5. Effect of other non-ionic detergents.
Several additional non-ionic detergents (Triton X-110, X-115 & X-405; Brij 
99; Tween 20 and Technicon Wetting agent W) were added to the assay buffer to 
final concentrations of 0,1 and 4% (v/v). A sample from the experiment described in 
section 8.2 (which gave a large increase in signal when Triton X-100 was added to the 
assay buffer) was analysed using the standard (a)-B assay protocol. The sample was 
diluted 1:1000 in assay buffer containing the aforementioned detergents.
Results.
Figure 8.4 shows that each of the detergents gave some increase in 
fluorescence signal when added to the assay buffer. This suggests that all groups of 
non-ionic detergent dissociate aggregated Lp(a). The experiment was repeated, but 
with substitution of the anti-apo B detection antibody with a europium labelled anti- 
apo (a) antibody. Once again, an increase in fluorescence signal was obtained 
although it was smaller than that obtained with the (a)-B assay (data not shown).
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8.6 Effect of other types of detergent.
Sodium salts of the bile salts, cholic and deoxycholic acid (anionic 
detergents), the cationic detergent, benzethonium chloride and the zwitterionic 
detergent, 3-[3-cholamidopropyl-dimethylammonio]-1 -propane-sulfonate (CHAPS), 
were each added to the assay buffer at concentrations up to 10 g/L. Benzethonium 
chloride, at concentrations greater than 1 g/L, was found to precipitate the protein 
constituents of the assay buffer, and therefore was only used at 1 g/L and below. The 
serum sample from the experiment in section 8.5 was analysed in an (a)-B assay after 
dilution in buffers containing one of each of these detergents.
8.6.1 Results.
Figure 8.5 shows that a marked decrease in fluorescence signal occurred when 
anionic and zwitterionic detergents were added to the assay buffer. This may be due 
to disruption of antigen-antibody binding or dénaturation of the antibody or antigen.
The effect of adding benzethonium chloride to the assay buffer was very 
interesting; an apparently massive signal increase was obtained when using assay 
buffer containing a relatively low concentration (1 g/L) of the detergent. This effect 
was investigated further by comparing the fluorescence signal obtained for an 
additional three serum samples (from the experiment in section 8.2) using microtitre 
plates coated with anti-apo(a) antibody and 'blocked' with 1% (w/v) BSA and in 
microtitre plates blocked' with 1% (w/v) BSA but with no antibody coating. Samples 
were analysed using the standard (a)-B assay protocol after dilution in assay buffers 
containing 0 or 0.5 g/L of benzethonium chloride. The fluorescence counts for each 
sample after dilution in buffer with or without benzethonium chloride (BCl) are 
presented in table 8.3.
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Table 8.3 : Fluorescence counts for three samples analysed using the (a)-B assay after 
dilution in assay buffer containing 0 (control) and 0.5 g/L benzethonium chloride 
(BCl).
Sample number Anti-apo (a) No antibody
1 control 212400 25000
1 (BCl 0.5 g/L) 469500 200000
2 control 387000 18000
2 (BCl 0.5 gÆ,) 644000 161000
3 control 295000 14800
3 (BCl 0.5 g/L) 639000 204000
It is apparent that a large proportion (55-70%) of the increase in fluorescence 
signal resulting from the presence of benzethonium chloride in the assay buffer was 
not due to binding of Lp(a) to the capture antibody. The reason for this was unclear.
The substitution of Triton X-100 for BCL in the experiment of table 8.3 did 
not reproduce the large increase in non-specific binding (data not shown). However, 
the possibility that the increase in fluorescence counts seen on addition Triton X-100 
to the assay buffer (figs 8.1 & 2) was simply an increase in non-specific binding 
cannot be discounted.
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8.7 Effect of Triton in commercial ELISA Lp(a) assays.
The increase in fluorescence signal seen when Triton X-100 was added to the 
assay buffer used to dilute samples in both the (a)-(a) and (a)-B time-resolved 
fluorescence Lp(a) assays suggested that a similar effect might be seen when the 
detergent is added to buffers used in commercial ELISA Lp(a) assays. This 
possibility was investigated using the Innotest® and Immunozym® ELISA kits. Triton 
X-100 at concentrations of 0, 1 and 4% (v/v) was added to the assay buffer and 
standard curves were generated using the manufacturer's assay protocol.
8.7.1 Results.
Figures 8.6 and 8.7 show the standard curves obtained using each kit with 
buffers containing each of the Triton concentrations. It may be seen that substantial 
decreases in absorbance occurred when Triton was added to the assay buffer in the 
Innotest® assay and a smaller absorbance decrease was obtained with the 
Immunozym® assay. The absorbance decreases seen in these kit assays may well be 
due to some form of inhibition of antigen binding to the capture antibody.
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8.8 Possible explanations for the anionic detergent-generated fluorescence 
signal increases.
The increase in fluorescence signal due to the presence of Triton in the assay 
buffer appears to be dependant upon many assay factors such as the capture antibody 
employed and detergent concentration in the assay buffer. In addition, variable 
increases in signal occurred between patients and standards. However, these signal 
increases were not been reproduced by addition of Triton to the buffers provided with 
commercial ELISA assays.
8.8.1 Method.
Antibody-coated microtitre plates used in the preceding experiments were 
blocked with 250pl of 1% (w/v) BSA. However, the possibility that this volume of 
solution might be insufficient to 'block' all of the microtitre plate well in contact with 
200pl of diluted sample or labelled antibody when shaken on a microtitre plate shaker 
was investigated. The volume of BSA solution was increased to 300p.l and a set of 
serum samples were analysed using microtitre plates coated with either anti-apo (a) or 
35f5 antibodies and 'blocked' with either 250|il or 300pl of BSA solution.
8.8.2 Results.
Table 8.4 shows the percentage increase in fluorescence signal (compared to 
the fluorescence signal for the sample analysed in the absence of Triton) for 4 
samples diluted in assay buffer containing 4% (v/v) Triton X-100. Samples were 
analysed using four different antibody combinations and microtitre plates blocked 
with 250pl or 300pl of 1% (w/v) BSA.
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Table 8.4.
Percentage increase in fluorescence signal (above control) when 4 serum samples 
were analysed using four antibody combinations and microtitre plates blocked with 
250pl or 300|il of 1% (w/v) BSA.
Antibody combination/Volume of BSA blocking solution
35f5 -B (a) -B 35f5 - (a ) (a) - (a)
Sample 250ul 300ul 250ul SOOul 250ul 300ul 250ul 300ul
1 -16 -18 +10 -7 -6 -1 +2 -6
2 -5 -14 +19 -2 -1 -4 +17 +8
3 +2 -39 +14 -22 +31 -10 +37 +6
4 -7 -27 +17 -13 -4 0 +30 +8
When using microtitre plates blocked with only 250|l i 1 of BSA solution 
significant increases in fluorescence signal were obtained for most samples on 
addition of Triton to the reaction buffer (particularly on the anti-apo (a) coated plates : 
e.g. sample 3 had a 37% increase in fluorescence signal on the (a)-(a) assay). 
However, 3 out of 4 samples analysed using the 35f5 coated microtitre plates showed 
a decrease in fluorescence signal on addition of Triton. When the volume of BSA 
blocking solution was increased to 300pl, increases in fluorescence signal were 
reduced, indeed many samples now gave a decrease in fluorescence signal in the 
presence of Triton. This was most apparent using the (a)-B antibody combination. 
The decreases in fluorescence signal suggested that (as in the commercial kit assays) 
Triton inhibited the binding of Lp(a) to the capture antibody.
This data therefore suggests that the increases in fluorescence signal were due 
to incomplete 'blocking' of microtitre plates rather than to any dissociation of 
aggregated Lp(a). The exact mechanism of the increase in fluorescence signal is 
unclear but probably involves non-specific binding of either apo B-containing 
proteins or europium-labelled detection antibodies to the microtitre plate wells.
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CONCLUSIONS.
The author hoped that the discovery of high molecular weight aggregates of 
Lp(a) in serum (that may be dissociated by detergents) might be a causative link 
between lipoprotein (a) and atherosclerosis. The apparent variability of the degree of 
Lp(a) aggregation between individuals might be a useful marker of those at risk of 
vascular deposition of Lp(a) as it is possible that individuals producing large Lp(a) 
aggregates may be more susceptible to vascular deposition of the lipoprotein. 
However, the apparent increases in Lp(a) concentration after treatment of serum with 
detergents was probably due to non-specific binding of one of the assay components, 
rather than to dissociation of Lp(a) aggregates.
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CHAPTER 9
FINAL DISCUSSION
170
The data presented in chapters 5 & 6 suggest that the time-resolved fluorescence 
assay gives results similar to those generated by commercial kit assays when used to measure 
Lp(a) concentrations in human serum samples. However, the time-resolved fluorescence 
assay has better analytical performance characteristics than any of these commercial assays. 
During this project (April 1992 - July 1994), two additional assays for the quantitation of 
Lp(a) were described in the literature, each with similar performance characteristics to the 
assay presented in this thesis. One of these assays also uses the time-resolved fluorescence 
approach while the other uses a chemiluminescent label No reference is made to 
these publications during development of the assay presented in this thesis. However, it is 
interesting that many of the problems encountered in this project were also encountered in 
these other studies.
The published time-resolved fluorescence assay used polyclonal (a)-(a) or (a)-B 
antibody combinations (see Chapter 5). Anti-apo (a) and anti-apo B antibodies were labelled 
with europium (21 and 17 europium atoms/IgG respectively) using a procedure identical to 
that used in this thesis. Microtitre plates were coated' overnight at 4®C by addition of 1.25 
pg of antibody/well. No additional 'blocking' step was adopted because a large sample 
dilution (1:10 000) in buffer containing both bovine serum albumin and bovine serum 
globulin was employed.
The assay was performed in two-steps, a 90 minute incubation of serum (diluted 1:10 
000) with the capture antibody at room temperature. After this incubation the microtitre plate 
was washed and immune complexes were detected by incubation with 50 ng of europium- 
labelled antibody for 60 minutes at room temperature. The assay performance characteristics 
for this procedure were slightly worse than those presented for the assay developed in this 
thesis. In particular, the assay was imprecise at low serum Lp(a) concentrations (Between- 
batch CV=15% at an Lp(a) concentration of 95 mg/L). This imprecision presumably results 
from the high sample dilution employed. However, the assay was sensitive (-2.5 mg/L) and 
had a wide working range (up to 1900 mg/L). In contrast to other assays described in this 
thesis, serum Lp(a) concentrations measured using the (a)-(a) antibody combination were 
higher than those obtained for the same samples using the (a)-B assay format.
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The chemiluminescent assay used a two-step approach with two conunercial (Dako) 
polyclonal antibodies; one directed against apo (a) the other against apo B. The assay takes 
less than 3 hours to perform and has an analytical working range of <5 to 800 mg/L using a 
1:10 dilution of serum. The within- and between-batch performance characteristics are 
similar to the time-resolved fluorescence assays. Results obtained using the (a)-(a) and (a)-B 
antibody combinations correlated very well, but Lp(a) results were -11% higher using the 
(a)-B assay (compared to the 40% difference seen in the assay developed in this thesis).
The problems of inter-assay variability in Lp(a) measurements appears, at present, to 
be insurmountable as each assay uses different calibration materials and antibodies. 
However, it may be that accurate determinations of seram Lp(a) may be unnecessary, a semi- 
quantitative result (normal or elevated) may give sufficient information to the clinician.
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